Document and Entity Information (USD $) In Millions, except Share data, unless otherwise specified	12 Months Ended
	Mar. 31, 2014	May 01, 2014	Sep. 30, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Brands Holdings, Inc.
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Mar. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		51,815,282
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 1,550.9

Consolidated Statements of Income and Comprehensive Income (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Revenues
Net sales	$ 596,954	$ 620,394	$ 437,838
Other revenues	4,927	3,203	3,247
Total revenues	601,881	623,597	441,085
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	261,830	276,381	213,701
Gross profit	340,051	347,216	227,384
Operating Expenses
Advertising and promotion	89,468	90,630	57,127
General and administrative	48,481	51,467	56,700
Depreciation and amortization	13,486	13,235	10,734
Total operating expenses	151,435	155,332	124,561
Operating income	188,616	191,884	102,823
Other (income) expense
Interest income	(60)	(13)	(18)
Interest expense	68,642	84,420	41,338
Gain on settlement	0	0	(5,063)
Loss on extinguishment of debt	18,286	1,443	5,409
Total other expense	86,868	85,850	41,666
Income before income taxes	101,748	106,034	61,157
Provision for income taxes	29,133	40,529	23,945
Net income	72,615	65,505	37,212
Earnings per share:
Basic (in USD per share)	$ 1.41	$ 1.29	$ 0.74
Diluted (in USD per share)	$ 1.39	$ 1.27	$ 0.73
Weighted average shares outstanding:
Basic (in shares)	51,641	50,633	50,270
Diluted (in shares)	52,349	51,440	50,748
Comprehensive income, net of tax:
Currency translation adjustments	843	(91)	(13)
Total other comprehensive income (loss)	843	(91)	(13)
Comprehensive income	$ 73,458	$ 65,414	$ 37,199

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Current assets
Cash and cash equivalents	$ 28,331	$ 15,670
Accounts receivable, net	65,050	73,053
Inventories	65,586	60,201
Deferred income tax assets	6,544	6,349
Prepaid expenses and other current assets	11,674	8,900
Total current assets	177,185	164,173
Property and equipment, net	9,597	9,896
Goodwill	190,911	167,546
Intangible assets, net	1,394,817	1,373,240
Other long-term assets	23,153	24,944
Total Assets	1,795,663	1,739,799
Liabilities and Stockholders’ Equity
Accounts payable	48,286	51,376
Accrued interest payable	9,626	13,894
Other accrued liabilities	26,446	31,398
Total current liabilities	84,358	96,668
Long-term debt
Principal amount	937,500	978,000
Less unamortized discount	(3,086)	(7,100)
Long-term debt, net of unamortized discount	934,414	970,900
Deferred income tax liabilities	213,204	194,288
Other long-term liabilities	327	0
Total Liabilities	1,232,303	1,261,856
Commitments and Contingencies – Note 17
Stockholders’ Equity
Preferred stock – $0.01 par value; Authorized – 5,000 shares; Issued and outstanding – None	0	0
Preferred share rights	0	283
Common stock-$0.01 par value; Authorized – 250,000 shares; Issued – 52,021 shares and 51,311 shares at March 31, 2014 and 2013, respectively	520	513
Additional paid-in capital	414,387	401,691
Treasury stock, at cost – 206 shares at March 31, 2014 and 181 shares at March 31, 2013	(1,431)	(687)
Accumulated other comprehensive income (loss), net of tax	739	(104)
Retained earnings	149,145	76,247
Total Stockholders’ Equity	563,360	477,943
Total Liabilities and Stockholders’ Equity	$ 1,795,663	$ 1,739,799

Consolidated Balance Sheets (Parentheticals) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	52,021,000	51,311,000
Treasury stock, shares	206,000	181,000

Consolidated Statements of Changes in Stockholders' Equity and Comprehensive Income (USD $) In Thousands, except Share data, unless otherwise specified	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive Loss	Preferred Share Rights	Retained Earnings (Accumulated Deficit)
Balances at Mar. 31, 2011	$ 361,832	$ 503	$ 387,932	$ (416)	$ 0	$ 0	$ (26,187)
Treasury stock, shares at Mar. 31, 2011				160,000
Common stock, shares at Mar. 31, 2011		50,276,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	3,078		3,078
Exercise of stock options	889	1	888
Exercise of stock options, shares	86,900	87,000
Preferred share rights	0					283	(283)
Issuance of shares related to restricted stock	1	1
Issuance of shares related to restricted stock, shares		103,000
Shares surrendered as payment of tax withholding	(271)			(271)
Shares surrendered as payment of tax withholding, shares				21,000
Components of comprehensive income:
Net income	37,212						37,212
Translation adjustments	(13)				(13)
Comprehensive income	37,199
Balances at Mar. 31, 2012	402,728	505	391,898	(687)	(13)	283	10,742
Treasury stock, shares at Mar. 31, 2012				181,000
Common stock, shares at Mar. 31, 2012		50,466,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	3,772		3,772
Exercise of stock options	6,029	7	6,022
Exercise of stock options, shares	786,500	786,000
Issuance of shares related to restricted stock		1	(1)
Issuance of shares related to restricted stock, shares	0	59,000
Components of comprehensive income:
Net income	65,505						65,505
Translation adjustments	(91)				(91)
Comprehensive income	65,414
Balances at Mar. 31, 2013	477,943	513	401,691	(687)	(104)	283	76,247
Treasury stock, shares at Mar. 31, 2013	181,000			181,000
Common stock, shares at Mar. 31, 2013		51,311,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	5,146		5,146
Exercise of stock options	5,907	6	5,901
Exercise of stock options, shares	605,000	605,000
Preferred share rights	0					(283)	283
Issuance of shares related to restricted stock	0	1	(1)
Issuance of shares related to restricted stock, shares		105,000
Treasury share repurchases	(744)			(744)
Excess tax benefits from share-based awards	1,650		1,650
Treasury share repurchases, shares				25,000
Components of comprehensive income:
Net income	72,615						72,615
Translation adjustments	843				843
Comprehensive income	73,458
Balances at Mar. 31, 2014	$ 563,360	$ 520	$ 414,387	$ (1,431)	$ 739	$ 0	$ 149,145
Treasury stock, shares at Mar. 31, 2014	206,000			206,000
Common stock, shares at Mar. 31, 2014		52,021,000

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2014 GSK Brands	Mar. 31, 2013 GSK Brands	Mar. 31, 2012 GSK Brands	Mar. 31, 2014 Care Pharma	Mar. 31, 2013 Care Pharma	Mar. 31, 2012 Care Pharma
Operating Activities
Net income	$ 72,615	$ 65,505	$ 37,212
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	13,486	13,235	10,734
Deferred income taxes	19,012	25,505	13,793
Amortization of deferred financing costs	7,102	9,832	1,630
Stock-based compensation costs	5,146	3,772	3,078
Loss on extinguishment of debt	18,286	1,443	5,409
Premium payment on 2010 Senior Notes	(15,527)	0	0
Amortization of debt discount	3,410	4,632	1,030
Lease termination costs	0	975	0
(Gain) loss on sale or disposal of property and equipment	(3)	103	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	9,735	(12,882)	(15,854)
Inventories	(2,850)	(9,342)	3,710
Prepaid expenses and other current assets	(2,130)	3,096	(3,009)
Accounts payable	(4,641)	24,677	5,127
Accrued liabilities	(12,059)	7,054	4,592
Net cash provided by operating activities	111,582	137,605	67,452
Investing Activities
Purchases of property and equipment	(2,764)	(10,268)	(606)
Proceeds from sale of property and equipment	3	15	0
Proceeds from escrow of Blacksmith acquisition	0	0	1,200
Proceeds from the sale of Phazyme brand	0	21,700	0
Acquisition of brands	(55,215)		(662,800)	0	0	(662,800)	(55,215)	0	0
Acquisition of brands from GSK purchase price adjustments	0	(226)	0
Net cash (used in) provided by investing activities	(57,976)	11,221	(662,206)
Financing Activities
Proceeds from issuance of Senior Notes	400,000	0	250,000
Proceeds from issuance of 2012 Term Loan	0	0	650,100
Repayment of 2010 Senior Notes	(250,000)	0	0
Repayment of 2010 Term Loan	0	0	(242,000)
Repayment of 2012 Term Loan	(157,500)	(190,000)	(25,000)
Payment of deferred financing costs	(7,466)	(1,146)	(33,284)
Repayments under revolving credit agreement	(83,000)	(15,000)	0
Borrowings under revolving credit agreement	50,000	48,000	0
Proceeds from exercise of stock options	5,907	6,029	889
Excess tax benefits from share-based awards	1,650	0	0
Fair value of shares surrendered as payment of tax withholding	(744)	0	(271)
Net cash (used in) provided by financing activities	(41,153)	(152,117)	600,434
Effects of exchange rate changes on cash and cash equivalents	208	(54)	1
Increase (decrease) in cash and cash equivalents	12,661	(3,345)	5,681
Cash and cash equivalents - beginning of year	15,670	19,015	13,334
Cash and cash equivalents - end of year	28,331	15,670	19,015
Interest paid	62,357	69,641	34,977
Income taxes paid	$ 11,020	$ 10,624	$ 12,865

Business and Basis of Presentation

12 Months Ended

Mar. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business and Basis of Presentation

Nature of Business

Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning brands to mass merchandisers, drug stores, supermarkets, club and dollar stores in the United States, Canada and certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 10 to these Consolidated Financial Statements.

Basis of Presentation

Our Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). All significant intercompany transactions and balances have been eliminated in consolidation. Our fiscal year ends on March 31st of each year. References in these Consolidated Financial Statements or notes to a year (e.g., “2014”) mean our fiscal year ended on March 31st of that year.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, sales returns and allowances, trade promotional allowances and inventory obsolescence.

Cash and Cash Equivalents

We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances, up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at March 31, 2014 are uninsured.

Accounts Receivable

We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers’ financial condition, (iii) monitor the payment history and aging of customers’ receivables, and (iv) monitor open orders against an individual customer’s outstanding receivable balance.

Inventories

Inventories are stated at the lower of cost or market value, where cost is determined by using the first-in, first-out method. We reduce inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year. Goodwill is tested for impairment at the reporting unit “brand” level, which is one level below the operating segment level.

Intangible Assets

Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives ranging from 3 to 30 years.

Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Deferred Financing Costs

We have incurred debt origination costs in connection with the issuance of long-term debt. These costs are capitalized as deferred financing costs and amortized over the term of the related debt using the effective interest method. For a further discussion regarding accelerated amortization, refer to Note 10 of these Consolidated Financial Statements.

Revenue Recognition

We recognize revenue when the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) the selling price is fixed or determinable; (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss; and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when product is received by the customer and, accordingly, we recognize revenue at that time. Provision is made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of the promotional program, the estimated amounts are adjusted to actual results.

Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Shipping, warehousing and handling costs were $32.0 million for 2014, $30.6 million for 2013 and $27.8 million for 2012.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred. Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores’ shelves in exchange for such fees.

Stock-based Compensation

We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is to be recognized over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period.

Income Taxes

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As a result, we have applied a more-likely-than-not recognition threshold for all tax uncertainties. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities.

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.

Recently Issued Accounting Standards

In April 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 is not expected to have a material impact on our Consolidated Financial Statements.

In July 2013, the FASB issued ASU 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, which requires that an unrecognized tax benefit, or portion of an unrecognized tax benefit, be presented as a reduction of a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward. If an applicable deferred tax asset is not available to use or the tax law of the applicable jurisdiction does not require the entity to use and the company does not intend to use the applicable deferred tax asset, the unrecognized tax benefit should be presented as a liability in the financial statements and should not be combined with an unrelated deferred tax asset. ASU 2013-11 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2013. The amendments must be applied prospectively to all unrecognized tax benefits that exist at the effective date; however retrospective application is permitted. ASU 2013-11 is not expected to have a material impact on our Consolidated Financial Statements.

In March 2013, the FASB issued ASU 2013-05, Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity, relating to the release of cumulative translation adjustments into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2013, and interim periods within those annual periods. Early adoption is permitted. The adoption of ASU 2013-05 is not expected to have a material impact on our Consolidated Financial Statements.

In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. ASU 2013-02 requires that for those items that are reclassified out of accumulated other comprehensive income and into net income in their entirety, the effect of the reclassification on each affected net income line item be disclosed. For accumulated other comprehensive income reclassification items that are not reclassified in their entirety into net income, a cross reference must be made to other required disclosures. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. ASU 2013-02 did not have a material impact on our Consolidated Financial Statements. See Note 15, Accumulated Other Comprehensive Income (Loss) for required disclosure.

In December 2011, the FASB issued ASU 2011-11, Disclosures about Offsetting Assets and Liabilities, regarding disclosures about offsetting assets and liabilities. The new disclosure requirements mandate that entities disclose both gross and net information about instruments and transactions eligible for offset in the statement of financial position, as well as instruments and transactions subject to an agreement similar to a master netting arrangement. In addition, the standard requires disclosure of collateral received and posted in connection with master netting agreements or similar arrangements. An entity will be required to disclose the following information for assets and liabilities within the scope of the new standard: (i) the gross amounts of those recognized assets and those recognized liabilities; (ii) the amounts offset to determine the net amounts presented in the statement of financial position; (iii) the net amounts presented in the statement of financial position; (iv) the amounts subject to an enforceable master netting arrangement or similar agreement not otherwise included in (ii); and (v) the net amount after deducting the amounts in (iv) from the amounts in (iii). The standard affects all entities with balances presented on a net basis in the financial statements, derivative assets and derivative liabilities, repurchase agreements, and financial assets and financial liabilities executed under a master netting or similar arrangement. This guidance is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. This new guidance did not have a material impact on our Consolidated Financial Statements.

Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References+ Details

Acquisitions

12 Months Ended

Mar. 31, 2014

Business Combinations [Abstract]

Acquisitions

Acquisition of Care Pharmaceuticals Pty Ltd.

On July 1, 2013, we completed the acquisition of Care Pharmaceuticals Pty Ltd. (“Care Pharma”), which was funded through a combination of our existing senior secured credit facility and cash on hand.

The Care Pharma brands include the Fess line of cold/allergy and saline nasal health products, which is the leading saline spray for both adults and children in Australia. Other key brands include Painstop analgesic, Rectogesic for rectal discomfort, and the Fab line of nutritional supplements. Care Pharma also carries a line of brands for children including Little Allergies, Little Eyes, and Little Coughs. The brands acquired are complementary to our existing OTC Healthcare portfolio.

This acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared a preliminary analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.



(In thousands)	July 1, 2013

Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Deferred income tax assets	283
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,386

Accounts payable	1,537
Accrued expenses	2,788
Other long term liabilities	300
Total liabilities assumed	4,625

Net assets acquired	$	56,761

Based on this analysis, we allocated $29.8 million to non-amortizable intangible assets and $1.7 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15.1 years. The weighted average remaining life for amortizable intangible assets at March 31, 2014 was 14.5 years.

We also recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the preliminary fair value of the net assets acquired. The full amount of goodwill is deductible for income tax purposes.

The pro-forma effect of this acquisition on revenues and earnings was not material.

Acquisition of GlaxoSmithKline OTC Brands

On December 20, 2011, we entered into two separate agreements with GlaxoSmithKline plc (“GSK”) to acquire a total of 17 North American OTC healthcare brands (the "GSK Brands") for $660.0 million in cash (the "GSK Agreement").

On January 31, 2012, we completed, subject to a post-closing inventory and apportionment adjustment, as defined in the GSK Agreement, the acquisition of the first 15 North American GSK Brands (the “GSK Brands I”), including the related contracts, trademarks and inventory for $615.0 million in cash. The GSK Brands I include, among other brands, BC, Goody's and Ecotrin brands of pain relievers; Beano, Gaviscon, Phazyme, Tagamet and Fiber Choice gastrointestinal brands; and the Sominex sleep aid brand.

On March 30, 2012, we completed, subject to a post-closing inventory and apportionment adjustment, as defined in the GSK Agreement, the acquisition of the Debrox and Gly-Oxide brands (the “GSK Brands II”) in the United States, including the related contracts, trademarks, and inventory for $45.0 million in cash.

Both the GSK Brands I and GSK Brands II are complementary to our existing OTC healthcare portfolio.

These acquisitions were accounted for in accordance with the Business Combinations topic of the ASC.

The purchase price of the GSK Brands I and GSK Brands II was funded by cash provided by the issuance of long-term debt and additional bank borrowings, which are discussed further in Note 11. In April 2012, we received the post-closing inventory and apportionment adjustments, attributable to both the GSK Brands I and GSK Brands II, which required us to pay an additional $2.8 million to GSK, and in May 2012 we received a revised post-closing inventory and apportionment adjustment, attributable to the GSK Brands II, which required us to pay an additional $0.2 million, for a total of $3.0 million, to GSK.

Concurrent with the closing of the GSK Brands I transaction, we entered into a Transitional Services Agreement with GSK (the “TSA”), whereby GSK provided us with various services including: marketing, operations, finance and other services, from the GSK Brands I acquisition date primarily through June 30, 2012, with additional finance support through August 31, 2012. As part of the TSA, GSK, among other things, shipped products, invoiced customers, collected from customers and paid certain vendors on our behalf. Our initial costs under the TSA were approximately $2.5 million per month for the length of the agreement and were reduced during the service period as we removed certain services and transitioned those processes to us. We incurred $6.9 million in TSA costs for the year ended March 31, 2013. Pursuant to the TSA, we received on a monthly basis the amount owed to us for revenues and expenses, net of GSK's TSA fees and inventory that GSK purchased on our behalf.

The allocation of the purchase price to assets acquired is based on a valuation we performed to determine the fair value of such assets as of the acquisition date. The following table summarizes our allocation of the $663.0 million purchase price to the assets we acquired on the GSK Brands acquisition dates:



(In thousands)	GSK Brands I (January 31, 2012)		GSK Brands II (March 30, 2012)		Total
Inventory	$	14,820	$	250	$	15,070
Prepaid expenses	3,575		—		3,575
Trade names	542,892		81,257		624,149
Goodwill	17,401		2,831		20,232
Total purchase price	$	578,688	$	84,338	$	663,026

We recorded goodwill based on the amount by which the purchase price exceeded the fair value of assets acquired. The amount of goodwill deductible for tax purposes is $20.2 million.

The fair value of the trade names is comprised of $556.9 million of non-amortizable intangible assets and $67.2 million of amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 19.3 years. The weighted average remaining life for amortizable intangible assets at March 31, 2014 was 17.0 years.

The operating results of the GSK Brands I have been included in our Consolidated Financial Statements beginning February 1, 2012, while the operating results of the GSK Brands II have been included in our Consolidated Financial Statements beginning April 1, 2012. Revenues of the GSK Brands for the year ended March 31, 2013 were $211.2 million and net income was $27.4 million.

The following table provides our combined unaudited pro forma revenues, income from continuing operations and income from continuing operations per basic and diluted common share as if the acquisition of the GSK Brands occurred on April 1, 2011. The pro forma results were prepared from financial information obtained from the sellers of the businesses, as well as information obtained during the due diligence processes associated with the acquisitions. The unaudited pro forma results reflect certain adjustments related to the acquisitions, such as increased depreciation and amortization expense resulting from the stepped-up basis to fair value of the assets acquired and adjustments to reflect the Company's borrowing and tax rates. This pro forma information is not necessarily indicative of either the combined results of operations that actually would have been realized by us had the acquisition of the GSK Brands been consummated at the beginning of the period for which the pro forma information is presented, or of future results.



	Year Ended March 31,
(In thousands, except per share data)	2012
	(Unaudited)
Revenues	$	616,849
Income from continuing operations	69,989

Basic earnings per share:
Income from continuing operations	$	1.39

Diluted earnings per share:
Income from continuing operations	$	1.38

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

+ Details

Divestitures

12 Months Ended

Mar. 31, 2014

Discontinued Operations and Disposal Groups [Abstract]

Divestitures

Sale of the Phazyme Brand

On October 31, 2012, we divested the Phazyme gas treatment brand, which was a non-core OTC brand that we acquired from GSK in January 2012. We received $21.7 million from the divestiture on October 31, 2012 and the remaining $0.6 million on January 4, 2013. The proceeds were used to repay debt. No significant gain or loss was recorded as a result of the sale.

Concurrent with the completion of the sale of the Phazyme brand, we entered into a Transitional Services Agreement with the buyer (the “Phazyme TSA”), whereby we agreed to provide the buyer with various services, including marketing, operations, finance and other services from the date of the acquisition primarily through January 31, 2013, with an option for additional support for the Canadian portion of that business through October 31, 2013, at the buyer's discretion. All Phazyme United States TSA services ended, as agreed, on January 31, 2013. The buyer elected to extend the Canadian portion of the TSA services on a month to month basis and terminated the support on October 31, 2013.

The following table presents the assets sold at October 31, 2012 related to the Phazyme brand:



(In thousands)	October 31, 2012
Components of assets sold:
Inventory	$	220
Prepaid expenses	100
Trade names	15,604
Goodwill	6,382

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

+ Details

Accounts Receivable

12 Months Ended

Mar. 31, 2014

Receivables [Abstract]

Accounts Receivable

Accounts receivable consist of the following:



(In thousands)	March 31,
	2014			2013
Components of Accounts Receivable
Trade accounts receivable	$	73,632		$	79,746
Other receivables	1,360			615
	74,992			80,361
Less allowances for discounts, returns and uncollectible accounts	(9,942		)	(7,308		)
Accounts receivable, net	$	65,050		$	73,053

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References+ Details

Inventories

12 Months Ended

Mar. 31, 2014

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following:



(In thousands)	March 31,
	2014		2013
Components of Inventories
Packaging and raw materials	$	3,099	$	1,875
Finished goods	62,487		58,326
Inventories	$	65,586	$	60,201

Inventories are carried and depicted above at the lower of cost or market, which includes a reduction in inventory values of $1.1 million and $1.3 million at March 31, 2014 and 2013, respectively, related to obsolete and slow-moving inventory.

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

Property and Equipment

12 Months Ended

Mar. 31, 2014

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment consist of the following:



(In thousands)	March 31,
	2014			2013
Components of Property and Equipment
Machinery	$	1,927		$	1,580
Computer equipment	8,923			6,559
Furniture and fixtures	1,858			1,510
Leasehold improvements	4,734			4,713
	17,442			14,362
Accumulated depreciation	(7,845		)	(4,466		)
Property and equipment, net	$	9,597		$	9,896

We recorded depreciation expense of $3.2 million, $1.6 million, and $0.7 million for 2014, 2013, and 2012, respectively. Additionally, during the year ended March 31, 2013, we wrote off leasehold improvements with a remaining net book value of less than $0.1 million due to the relocation of our corporate offices.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

Goodwill

12 Months Ended

Mar. 31, 2014

Goodwill [Abstract]

Goodwill

The following table summarizes the changes in the carrying value of goodwill by operating segment for each of 2012, 2013, and 2014:



(In thousands)	OTC Healthcare			Household Cleaning			Consolidated
Balance – March 31, 2011
Goodwill	$	277,677		$72,549			$350,226
Accumulated impairment losses	(130,170		)	(65,160		)	(195,330		)
Balance – March 31, 2011	147,507			7,389			154,896

2012 additions	20,006			—			20,006

Balance – March 31, 2012
Goodwill	296,483			72,549			369,032
Accumulated impairment losses	(130,170		)	(65,160		)	(195,330		)
Balance – March 31, 2012	166,313			7,389			173,702

2013 additions	226			—			226
2013 reductions	(6,382		)	—			(6,382		)

Balance – March 31, 2013
Goodwill	290,327			72,549			362,876
Accumulated impairment losses	(130,170		)	(65,160		)	(195,330		)
	160,157			7,389			167,546

2014 additions	23,122			—			23,122
Effects of foreign currency exchange rates	243			—			243

Balance – March 31, 2014
Goodwill	313,692			72,549			386,241
Accumulated impairment losses	(130,170		)	(65,160		)	(195,330		)
	$	183,522		$	7,389		$	190,911

As discussed in Note 2, on January 31, 2012, we completed the acquisition of the GSK Brands I for $615.0 million in cash, and on March 30, 2012, we completed the acquisition of the GSK Brands II for $45.0 million in cash, in each case subject to certain post-closing adjustments. We recorded a post-closing adjustment of $2.8 million as of March 31, 2012, to reflect adjustments to certain inventory items and other current assets acquired. In connection with these acquisitions, we recorded goodwill of $20.0 million based on the amount by which the purchase price exceeded the fair value of assets acquired.

During the three months ended June 30, 2012, we received a revised post-closing inventory and apportionment adjustment from GSK for an additional amount of $0.2 million, which resulted in an increase to our recorded goodwill balance.

As more fully disclosed in Note 3, on October 31, 2012, we sold the Phazyme brand for $22.3 million. As a result of the divestiture of Phazyme, we reduced goodwill by $6.4 million.

As discussed in Note 2, on July 1, 2013, we completed the acquisition of Care Pharma. In connection with this acquisition, we recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the preliminary fair value of the net assets acquired.

Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. At March 31, 2014 and 2013, in conjunction with the annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in 2014 or 2013.

The discounted cash flow methodology is a widely-accepted valuation technique utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at March 31, 2014, 2013 and 2012, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. Although the impairment charges in the prior years were a result of utilizing management’s best estimate of fair value, the estimates and assumptions made in assessing the fair value of the our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require additional impairments in the future. The Company has experienced revenue declines in regard to certain brands in its Household Cleaning segment during 2013 and 2012. Adverse changes in the expected operating results and/or unfavorable changes in other economic factors used to estimate fair values of these specific brands could result in a non-cash impairment charge in the future.

The aggregate fair value of our goodwill and indefinite-lived intangible assets exceeded the carrying value by 53.1%. Only one individual reporting unit's fair value exceeded its carrying values by less than 10.0%. The reporting unit's associated carrying value of goodwill and intangible assets amounted to $0.8 million at March 31, 2014. Additionally, certain brands, including certain of our household brands, have experienced recent revenue declines. While the fair value of these reporting units exceeds the carrying value by more than 10.0%, should such revenue declines continue, the fair value of the corresponding reporting units may no longer exceed their carrying value and we would be required to record an impairment charge.

Intangible Assets

12 Months Ended

Mar. 31, 2014

Intangible Assets [Abstract]

Intangible Assets

A reconciliation of the activity affecting intangible assets for each of 2012, 2013, and 2014 is as follows:



(In thousands)	Year Ended March 31, 2012
	Indefinite Lived Trademarks		Finite Lived Trademarks		Non Compete Agreement		Totals
Gross Amount
Balance – March 31, 2011 (including discontinued operations)	$	688,484	$	150,293	$	158	$	838,935
Additions	556,930		67,219		—		624,149
Disposals	—		—		—		—
Balance – March 31, 2012	$	1,245,414	$	217,512	$	158	$	1,463,084

Accumulated Amortization
Balance – March 31, 2011	$	—	$	52,416	$	158	$	52,574
Additions	—		9,988		—		9,988
Disposals	—		—		—		—
Balance – March 31, 2012	$	—	$	62,404	$	158	$	62,562

Intangibles, net – March 31, 2012	$	1,245,414	$	155,108	$	—	$	1,400,522



(In thousands)	Year Ended March 31, 2013
	Indefinite Lived Trademarks			Finite Lived Trademarks			Non Compete Agreement		Totals
Gross Amount
Balance – March 31, 2012	$	1,245,414		$	217,512		$	158	$	1,463,084
Reclassifications	(1,696		)	1,696			—		—
Reductions	—			(16,142		)	—		(16,142		)
Balance – March 31, 2013	$	1,243,718		$	203,066		$	158	$	1,446,942

Accumulated Amortization
Balance – March 31, 2012	$	—		$	62,404		$	158	$	62,562
Additions	—			11,678			—		11,678
Reductions	—			(538		)	—		(538		)
Balance – March 31, 2013	$	—		$	73,544		$	158	$	73,702

Intangibles, net – March 31, 2013	$	1,243,718		$	129,522		$	—	$	1,373,240



(In thousands)	Year Ended March 31, 2014
	Indefinite Lived Trademarks		Finite Lived Trademarks		Non Compete Agreement			Totals
Gross Amount
Balance – March 31, 2013	$	1,243,718	$	203,066	$	158		$	1,446,942
Additions	29,845		1,657		—			$	31,502
Reductions	—		—		(158		)	(158		)
Effects of foreign currency exchange rates	315		17		—			332
Balance – March 31, 2014	$	1,273,878	$	204,740	$	—		$	1,478,618

Accumulated Amortization
Balance – March 31, 2013	$	—	$	73,544	$	158		$	73,702
Additions	—		10,256		—			10,256
Reductions	—		—		(158		)	(158		)
Effects of foreign currency exchange rates	—		1		—			1
Balance – March 31, 2014	$	—	$	83,801	$	—		$	83,801

Intangibles, net – March 31, 2014	$	1,273,878	$	120,939	—			$	1,394,817

As discussed in Note 2, on January 31, 2012, we completed the acquisition of the GSK Brands I for $615.0 million in cash. On March 30, 2012, we completed the acquisition of the GSK Brands II for $45.0 million in cash. In connection with these acquisitions, we allocated $624.1 million of the purchase price to intangible assets.

As discussed in Note 3, on October 31, 2012, we sold the Phazyme brand for $22.3 million. As a result of this divestiture, we reduced the net book value of our intangible assets by $15.6 million.

During the year ended March 31, 2013, we reclassified a portion of trademarks related to the acquired GSK Brands from indefinite-lived to finite-lived intangible assets in the amount of $1.7 million.

As discussed in Note 2, on July 1, 2013, we completed the acquisition of Care Pharma. In connection with this acquisition, we allocated $31.5 million to intangible assets based on our analysis.

We completed our test for impairment of intangible assets during the fourth quarter of 2014, 2013 and 2012. For 2014, 2013 and 2012, we did not record any impairment charge, as facts and circumstances indicated that the fair values of the intangible assets for such segments exceeded their carrying values. The Company has experienced revenue declines in regard to certain brands in its Household Cleaning segment during 2013 and 2012. Adverse changes in the expected operating results and/or unfavorable changes in other economic factors used to estimate fair values of these specific brands could result in a non-cash impairment charge in the future.

The weighted average remaining life for finite-lived intangible assets at March 31, 2014 was approximately 13.5 years and the amortization expense for the year ended March 31, 2014 was $10.3 million. At March 31, 2014, finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 3 to 30 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):



Year Ending March 31,
2015	$	8,950
2016	8,950
2017	8,950
2018	8,950
2019	8,950
Thereafter	76,189
	$	120,939

Long-Term Debt

12 Months Ended

Mar. 31, 2014

Debt Disclosure [Abstract]

Long-Term Debt

2010 Senior Notes:

On March 24, 2010, Prestige Brands, Inc. (the "Borrower") issued $150.0 million aggregate principal amount of senior unsecured notes, with an interest rate of 8.25% and a maturity date of April 1, 2018 (the "2010 Senior Notes"). On November 1, 2010, the Borrower issued an additional $100.0 million of the 2010 Senior Notes. The Borrower had the right to earlier redeem some or all of the 2010 Senior Notes at redemption prices set forth in the indenture governing the 2010 Senior Notes. The 2010 Senior Notes issued in March and November 2010 were issued at an aggregate face value of $150.0 million and $100.0 million, respectively, with a discount to the initial purchasers of $2.2 million and a premium of $0.3 million, respectively, and net proceeds to the Company of $147.8 million and $100.3 million, respectively, yielding an 8.5% effective interest rate for the 2010 Senior Notes on a combined basis. The 2010 Senior Notes were unconditionally guaranteed by Prestige Brands Holdings, Inc. and its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees was joint and several. There were no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. On December 17, 2013, we offered to redeem the 2010 Senior Notes at a premium of 6.33%, of which $201.7 million were redeemed on that date. The remaining $48.3 million were redeemed on January 16, 2014. As a result, during the quarter ended December 31, 2013, we recorded a $15.0 million loss on the early extinguishment of debt relating to the $201.7 million 2010 Senior Notes redeemed and recorded an additional loss of $3.3 million on the remaining $48.3 million tendered on January 16, 2014. The $18.3 million loss consists of premium payments of $15.5 million, write-off of deferred financing costs of $2.2 million, and write-off of debt discount of $0.6 million.

2012 Senior Notes:

On January 31, 2012, the Borrower issued $250.0 million aggregate principal amount of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower may earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2012 Senior Notes.

2012 Term Loan and 2012 ABL Revolver:

On January 31, 2012, the Borrower also entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a seven-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a five-year maturity. In September 2012, we utilized a portion of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $25.0 million to $75.0 million, and in June 2013, we further increased the amount of our borrowing capacity under the 2012 ABL Revolver by $20.0 million to $95.0 million and also reduced our borrowing rate on the 2012 ABL Revolver by 0.25%. The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Company of $650.1 million. In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

On February 21, 2013, the Borrower entered into Amendment No. 1 (the "Amendment") to the 2012 Term Loan. The Amendment provides for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans. The interest rate on the Term B-1 Loans is based, at the Borrower's option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin. The new Term B-1 Loans will mature on the same date as the Term B Loans' original maturity date. In addition, the Amendment provides the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with the Amendment, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt.

The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 2.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, with a LIBOR floor of 1.00%. For the twelve months ended March 31, 2014, the average interest rate on the 2012 Term Loan was 3.9%.

Under the 2012 Term Loan, we were originally required to make quarterly payments each equal to 0.25% of the original principal amount of the 2012 Term Loan, with the balance expected to be due on the seventh anniversary of the closing date. However, since we have previously made significant optional payments that exceeded all of our required quarterly payments, we will not be required to make a payment until the maturity date of January 31, 2019.

Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the twelve months ended March 31, 2014, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 2.0%.

We used the net proceeds from the 2012 Senior Notes offering, together with borrowings under the 2012 Term Loan, to finance the acquisition of the GSK Brands, to repay the balance of our then-outstanding credit facility, to pay fees and expenses incurred in connection with these transactions and for general corporate purposes.

2013 Senior Notes:

On December 17, 2013, the Borrower issued $400.0 million aggregate principal amount of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $7.2 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes.

Redemptions and Restrictions:

At any time prior to February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a "make-whole premium" calculated as set forth in the indenture governing the 2012 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at redemption prices set forth in the indenture governing the 2012 Senior Notes. In addition, at any time prior to February 1, 2015, we may redeem up to 35% of the aggregate principal amount of the 2012 Senior Notes at a redemption price equal to 108.125% of the principal amount, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2012 Senior Notes, the Borrower will be required to make an offer to purchase the 2012 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2012 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

At any time prior to December 15, 2016, we may redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, to the redemption date on the 2013 Senior Notes plus an applicable "make-whole premium". On or after December 15, 2016, we may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we may redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met.

The indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes. At March 31, 2014, we were in compliance with the covenants under our long-term indebtedness.

At March 31, 2014, we had an aggregate of $23.2 million of unamortized debt issuance costs and $3.1 million of unamortized debt discount, the total of which is comprised of $10.1 million related to the 2012 Senior Notes, $7.0 million related to the 2013 Senior Notes, $7.9 million related to the 2012 Term Loan, and $1.3 million related to the 2012 ABL Revolver.

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	March 31,
	2014			2013
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year, commencing June 15, 2014. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	—
2012 Senior Notes bearing interest at 8.125%, with interest only payable on February 1st and August 1st of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
2012 Term Loan bearing interest at the Company's option at either a base rate plus applicable margin with a floor of 2.00% or LIBOR with a floor of 1.00%, due on January 31, 2019.	287,500			445,000
2012 ABL Revolver bearing interest at the Company's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	—			33,000
2010 Senior Notes bearing interest at 8.25%, with interest only payable on April 1st and October 1st of each year. The 2010 Senior Notes would have matured on April 1, 2018.	—			250,000
	937,500			978,000
Current portion of long-term debt	—			—
	937,500			978,000
Less: unamortized discount	(3,086		)	(7,100		)
Long-term debt, net of unamortized discount	$	934,414		$	970,900

As of March 31, 2014, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows:



Year Ending March 31,	Amount
2015	$	—
2016	—
2017	—
2018	—
2019	287,500
Thereafter	650,000
	$	937,500

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Mar. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements As we deem appropriate, we may from time to time utilize derivative financial instruments to mitigate the impact of changing interest rates associated with our long-term debt obligations or other derivative financial instruments. While we have utilized derivative financial instruments in the past, we did not have any significant derivative financial instruments outstanding at March 31, 2014, 2013 or 2012. We have not entered into derivative financial instruments for trading purposes; all of our derivatives were over-the-counter instruments with liquid markets. For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. The Fair Value Measurements and Disclosures topic of the FASB ASC requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2012 Term Loan, the 2013 and the 2012 Senior Notes, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. At March 31, 2013, the 2010 Senior Notes were measured at Level 2 of the above hierarchy. At March 31, 2014 and 2013, we did not have any assets or liabilities measured in Level 1 or 3. During 2014, 2013 and 2012, there were no transfers of assets or liabilities between Levels 1, 2 and 3. At March 31, 2014, the carrying value and market value of our 2013 Senior Notes was $400.0 million and $408.5 million, respectively. At March 31, 2014 and 2013, the carrying value of our 2012 Senior Notes was $250.0 million. The market value of our 2012 Senior Notes was $280.6 million and $281.9 million at March 31, 2014 and 2013, respectively. At March 31, 2014 and 2013, the carrying value of the 2012 Term Loan was $287.5 million and $445.0 million, respectively. The market value of the 2012 Term Loan was $288.9 million and $451.1 million at March 31, 2014 and 2013, respectively. During the year ended March 31, 2014, we repaid the 2010 Senior Notes in full. At March 31, 2013, the carrying value and market value of our 2010 Senior Notes was $250.0 million and $271.9 million, respectively. During the year ended March 31, 2014 we repaid the existing balance of the 2012 ABL Revolver in full. At March 31, 2013, the carrying value of the 2012 ABL Revolver of $33.0 million, approximated its market value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References+ Details

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Mar. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through March 31, 2014. Pursuant to the provisions of various employee restricted stock awards, we repurchased 25,464 shares of restricted common stock from our employees during the year ended March 31, 2014. During the year ended March 31, 2013, we did not repurchase any shares of restricted common stock from our employees pursuant to the provisions of the various employee restricted stock awards. The repurchases during the year ended March 31, 2014 were at an average price of $29.23. All of the repurchased shares have been recorded as treasury stock.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Earnings Per Share

12 Months Ended

Mar. 31, 2014

Earnings Per Share [Abstract]

Earnings Per Share

Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, restricted stock awards, and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share:



(In thousands, except per share data)	Year Ended March 31,
	2014		2013		2012
Numerator
Net income	$	72,615	$	65,505	$	37,212

Denominator
Denominator for basic earnings per share- weighted average shares outstanding	51,641		50,633		50,270
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	708		807		478
Denominator for diluted earnings per share	52,349		51,440		50,748

Earnings per Common Share:
Basic net earnings per share	$	1.41	$	1.29	$	0.74

Diluted net earnings per share	$	1.39	$	1.27	$	0.73

Additionally, for 2014, 2013, and 2012 there were 0.2 million, zero, and 0.4 million shares attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

- Definition

The entire disclosure for earnings per share.

+ References+ Details

Share-Based Compensation

12 Months Ended

Mar. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-based Compensation

Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”) which provides for the grant, up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During 2014, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $5.1 million and $1.5 million, respectively.

During 2013, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $3.8 million and $1.2 million, respectively.

During 2012, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $3.1 million and $1.2 million, respectively. During 2012 management determined that performance goals associated with the grants of stock to management and employees in May 2008 were met, and accordingly recorded stock compensation costs and issued shares in accordance with the Plan in May 2011. No prior compensation costs were required to be reversed.

Restricted Shares

Restricted shares granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The restricted share awards provide for accelerated vesting if there is a change of control, as defined in the Plan. The restricted stock units granted to employees generally vest in their entirety on the three-year anniversary of the date of the grant. Termination of employment prior to vesting will result in forfeiture of the restricted stock units. The restricted stock units granted to directors will vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, with the settlement in common stock to occur on the earliest of the director's death, disability or six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. Upon vesting, the units will be settled in shares of our common stock.

On January 25, 2012, the Compensation Committee of our Board of Directors granted 95,000 restricted stock units to certain members of executive management. The restricted stock units will vest in equal annual installments over a three-year period on the anniversary date of the grants. The grant-date fair value of restricted shares is determined using the closing price of our common stock on the day of grant. On May 9, 2012, the Compensation Committee of our Board of Directors granted 111,152 restricted stock units to certain executive officers and employees under the Plan, which will vest 33.3% per year over three years. On June 29, 2012, the Compensation Committee of our Board of Directors granted 12,652 restricted stock units to the independent members of the Board of Directors under the Plan. On August 6, 2012, the Compensation Committee of the Board of Directors granted 5,109 restricted stock units to Matthew M. Mannelly, our President and CEO, under the Plan. On May 14, 2013, the Compensation Committee of our Board of Directors granted 113,637 restricted stock units to certain executive officers and employees under the Plan. Of those grants, 55,637 restricted stock units vest in their entirety on the three-year anniversary of the date of grant, and 58,000 restricted stock units vest 33.3% per year over three years. On July 29, 2013, the Compensation Committee of the Board of Directors granted 7,004 restricted stock units to the independent members of the Board of Directors under the Plan. On November 5, 2013, the Compensation Committee of our Board of Directors granted 6,000 restricted stock units to certain employees under the Plan, which will vest 33.3% per year over three years.

The weighted-average grant-date fair value during 2014, 2013, and 2012 was $30.19, $13.59, and $11.81, respectively.

A summary of the Company’s restricted shares granted under the Plan is presented below:



Restricted Shares	Shares (in thousands)		Weighted-Average Grant-Date Fair Value

Vested and Nonvested at March 31, 2011	275.4		$	8.46

Granted	217.5		11.81
Vested and issued	(103.4	)	9.93
Forfeited	(26.1	)	10.17
Vested and nonvested at March 31, 2012	363.4		9.92
Vested at March 31, 2012	54.0		7.40

Granted	128.9		13.59
Vested and issued	(58.7	)	9.99
Forfeited	(12.3	)	10.69
Vested and nonvested at March 31, 2013	421.3		11.01
Vested at March 31, 2013	70.4		8.52

Granted	126.6		30.19
Vested and issued	(104.8	)	9.98
Forfeited	(5.6	)	15.11
Vested and nonvested at March 31, 2014	437.5		16.76
Vested at March 31, 2014	69.6		9.34

Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management’s estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted option.

On May 9, 2012, the Compensation Committee of our Board of Directors granted stock options to acquire 422,962 shares of our common stock to certain executive officers and employees under the Plan. These stock options were granted at an exercise price of $13.24 per share, which is equal to the closing price for our common stock on the date of the grant. On August 6, 2012, the Compensation Committee of the Board of Directors granted stock options to acquire 21,978 shares of our common stock to Matthew M. Mannelly. These stock options were granted at an exercise price of $15.66 per share, which is equal to the closing price for our common stock on the date of grant. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. On May 14, 2013, the Compensation Committee of our Board of Directors granted stock options to acquire 227,672 shares of our common stock to certain executive officers and employees under the Plan. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $29.94 per share, which is equal to the closing price for our common stock on the date of the grant.

The weighted-average grant-date fair value of the options granted during 2014, 2013, and 2012 were $13.94, $6.03, and $5.83, respectively.



	Year Ended March 31,
	2014		2013
Expected volatility	48.0	%	44.0	%
Expected dividends	—		—
Expected term in years	6		6.5
Risk-free rate	1.3	%	1.2	%

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)

Outstanding at March 31, 2011	1,621.5		$	8.19

Granted	308.2		11.27
Exercised	(86.9	)	10.24
Forfeited or expired	(97.4	)	11.57
Outstanding at March 31, 2012	1,745.4		8.44

Granted	444.9		13.36
Exercised	(786.5	)	7.67
Forfeited or expired	(17.4	)	11.21
Outstanding at March 31, 2013	1,386.4		10.43

Granted	227.7		29.94
Exercised	(605.0	)	9.76
Forfeited or expired	(14.2	)	14.56
Outstanding at March 31, 2014	994.9		15.24		7.4	$	7,387
Exercisable at March 31, 2014	173.6		11.56		6.8	1,181

The aggregate intrinsic value of options exercised during 2014 was $14.0 million.

At March 31, 2014, there were $3.7 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management’s estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 0.9 years. The total fair value of options and restricted stock units vested during 2014, 2013, and 2012 was $3.4 million, $2.5 million and $2.9 million, respectively. Cash received from the exercise of stock options was $5.9 million during 2014, and we realized $1.7 million in tax benefits for the tax deductions resulting from option exercises in 2014. Cash received from the exercise of stock options was $6.0 million during 2013, and we realized $11.3 million in tax benefits for the tax deductions resulting from option exercises in 2013. Cash received from the exercise of stock options was $0.6 million during 2012, and we realized $0.3 million in tax benefits for the tax deductions from option exercises in 2012. At March 31, 2014, there were 1.6 million shares available for issuance under the Plan.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

Income Taxes

12 Months Ended

Mar. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

The provision for income taxes consists of the following:



(In thousands)	Year Ended March 31,
	2014			2013		2012
Current
Federal	$	7,801		$	12,520	$	8,127
State	625			1,972		1,396
Foreign	1,675			532		630
Deferred
Federal	27,045			23,845		13,100
State	(7,879		)	1,660		692
Foreign	(134		)	—		—
Total provision for income taxes	$	29,133		$	40,529	$	23,945

The principal components of our deferred tax balances are as follows:



(In thousands)	March 31,
	2014			2013
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$	4,082		$	2,807
Inventory capitalization	1,301			1,370
Inventory reserves	362			525
Net operating loss carryforwards	327			411
State income taxes	3,728			7,364
Accrued liabilities	642			1,896
Stock compensation	2,358			2,367
Other	702			496
Total deferred tax assets	13,502			17,236

Deferred Tax Liabilities
Property and equipment	(1,467		)	(1,504		)
Intangible assets	(218,696		)	(203,671		)
Total deferred tax liabilities	(220,163		)	(205,175		)

Net deferred tax liability	$	(206,661	)	$	(187,939	)

At March 31, 2014, a 100% owned subsidiary of the Company had a net operating loss carryforward of approximately $0.9 million, which may be used to offset future taxable income of the consolidated group and begins to expire in 2020. The Company expects to fully utilize the loss carryover before it expires. The net operating loss carryforward is subject to an annual limitation as to usage under Internal Revenue Code Section 382 of approximately $0.2 million.

A reconciliation of the effective tax rate compared to the statutory U.S. Federal tax rate is as follows:



	Year Ended March 31,
(In thousands)	2014					2013					2012
				%					%					%
Income tax provision at statutory rate	$	35,612		35.0		$	37,112		35.0		$	21,405		35.0
Foreign tax (benefit) provision	(918		)	(0.9	)	—			—		191			0.3
State income taxes, net of federal income tax benefit	2,004			2.0		3,413			3.2		2,073			3.4
Decrease in net deferred tax liability resulting from a change in the effective state tax rate	(8,892		)	(8.7	)	(1,741		)	(1.6	)	(1,177		)	(1.9	)
Nondeductible compensation	1,011			1.0		1,684			1.6		1,305			2.1
Other	316			0.3		61			—		148			0.3
Total provision for income taxes	29,133			28.7		40,529			38.2		23,945			39.2

Uncertain tax liability activity is as follows:



	2014			2013
(In thousands)
Balance – beginning of year	$	1,016		292
Additions based on tax positions related to the current year	360			831
Reductions based on lapse of statute of limitations	(140		)	(107		)
Balance – end of year	$	1,236		$	1,016

We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in 2013 or 2014. We do not anticipate any events or circumstances that would cause a significant change to these uncertainties during 2015. We are subject to taxation in the United States and various state and foreign jurisdictions and we are generally open to examination from the year ended March 31, 2011 forward.

The Company does not provide for United States income taxes on the undistributed earnings of foreign subsidiaries, which are intended to be indefinitely reinvested in operations outside of the United States. As of March 31, 2014, the cumulative amount of earnings upon which United States income taxes have not been provided is approximately $4.7 million. As of March 31, 2014, the amount of unrecognized deferred tax liability related to these earnings is estimated to be $0.4 million.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

Commitments and Contingencies

12 Months Ended

Mar. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

We are involved from time to time in routine legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess probability and amount of potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results from operations.

Lease Commitments

We have operating leases for office facilities and equipment in New York and Wyoming, which expire at various dates through 2018. Due to the acquisition of the GSK Brands, we required additional office space and entered into a 5.5 year lease for a new office facility in New York, which began in the third quarter of fiscal 2013. In May 2012, we also entered into a three year office lease in Rogers, Arkansas. These amounts have been included in the schedule below.

The following summarizes future minimum lease payments for our operating leases:



(In thousands)	Facilities		Equipment		Total
Year Ending March 31,
2015	$	1,221	$	136	$	1,357
2016	994		135		1,129
2017	1,023		68		1,091
2018	1,044		—		1,044
2019	—		—		—
	$	4,282	$	339	$	4,621

Rent expense was $1.5 million, $1.2 million, and $0.9 million for 2014, 2013, and 2012, respectively.

Purchase Commitments

Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products. Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.



(In thousands)
Year Ending March 31,
2015	1,105
2016	1,074
2017	1,044
2018	1,013
2019	982
Thereafter	560
	$	5,778

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

Concentrations of Risk	12 Months Ended
Concentrations of Risk	Mar. 31, 2014
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products. We sell our products to mass merchandisers, food and drug stores, and dollar and club stores. During 2014, 2013, and 2012, approximately 38.3%, 40.5%, and 51.3%, respectively, of our total sales were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. During 2014, 2013, and 2012, Walmart accounted for approximately 19.5%, 15.9%, and 18.9%, respectively, of our gross revenues. At March 31, 2014, approximately 24.1% of accounts receivable were owed by the same customer. We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri. A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center. As a result, any such disruption could have a material adverse effect on our business, sales and profitability. At March 31, 2014, we had relationships with 50 third-party manufacturers. Of those, we had long-term contracts with 24 manufacturers that produced items that accounted for approximately 82.4% of our gross sales for 2014, compared to 22 manufactures with long-term contracts that accounted for approximately 75.3% of gross sales in 2013. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business, financial condition, and results from operations.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References+ Details

Business Segments

12 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

Business Segments

Segment information has been prepared in accordance with Segment Reporting topic of the FASB ASC 280 and includes certain information that our chief operating decision maker, the Company's Chief Executive Officer, reviews, including contribution margin, which is a non-GAAP financial measure. Contribution margin is defined as gross profit less advertising and promotional expenses. Our general and administrative expenses and other corporate-level activity is not allocated to our segments, including costs of: employee-related costs; legal; finance; information technology; corporate development; legal settlements; depreciation and amortization; and facility and insurance costs. Our current operating and reportable segments consist of (i) OTC Healthcare and (ii) Household Cleaning.

There were no inter-segment sales or transfers during any of the periods presented. We evaluate the performance of our operating segments and allocate resources to them based primarily on contribution margin.

The table below summarizes information about our operating and reportable segments.



	Year Ended March 31, 2014
	OTC Healthcare		Household Cleaning		Consolidated
(In thousands)
Net sales	$	513,056	$	83,898	$	596,954
Other revenues	791		4,136		4,927
Total revenues	513,847		88,034		601,881
Cost of sales	197,442		64,388		261,830
Gross profit	316,405		23,646		340,051
Advertising and promotion	86,578		2,890		89,468
Contribution margin	$	229,827	$	20,756	250,583
Other operating expenses					61,967
Operating income					188,616
Other expense					86,868
Income before income taxes					101,748
Provision for income taxes					29,133
Net income					$	72,615



	Year Ended March 31, 2013
	OTC Healthcare		Household Cleaning		Consolidated
(In thousands)
Net sales	$	536,247	$	84,147	$	620,394
Other revenues	684		2,519		3,203
Total revenues	536,931		86,666		623,597
Cost of sales	211,654		64,727		276,381
Gross profit	325,277		21,939		347,216
Advertising and promotion	84,537		6,093		90,630
Contribution margin	$	240,740	$	15,846	256,586
Other operating expenses					64,702
Operating income					191,884
Other expense					85,850
Income before income taxes					106,034
Provision for income taxes					40,529
Net income					$	65,505



	Year Ended March 31, 2012
	OTC Healthcare		Household Cleaning		Consolidated
(In thousands)
Net sales	$	344,282	$	93,556	$	437,838
Other revenues	719		2,528		3,247
Total revenues	345,001		96,084		441,085
Cost of sales	143,151		70,550		213,701
Gross profit	201,850		25,534		227,384
Advertising and promotion	51,895		5,232		57,127
Contribution margin	$	149,955	$	20,302	170,257
Other operating expenses					67,434
Operating income					102,823
Other expense					41,666
Income before income taxes					61,157
Provision for income taxes					23,945
Net income					$	37,212



	Year Ended March 31,
(In thousands)	2014		2013		2012
Analgesics	$	110,604	$	108,144	$	18,930
Cough & Cold	115,241		126,974		116,669
Gastrointestinal	83,971		97,940		29,489
Eye & Ear Care	86,390		86,380		74,363
Dermatologicals	52,363		52,401		52,592
Oral Care	48,774		49,617		46,551
Other OTC	16,504		15,475		6,407
Total OTC Healthcare Segment	513,847		536,931		345,001
Household Cleaning Segment	88,034		86,666		96,084
Consolidated Net Revenues	$	601,881	$	623,597	$	441,085

During 2014, 2013, and 2012, approximately 86.9%, 89.9%, and 90.2%, respectively of our sales were made to customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented. Sales to Canada accounted for 7.7%, 7.4%, and 6.3% of our total revenues for 2014, 2013, and 2012, respectively. At March 31, 2014, substantially all of our long-term assets were located in the United States of America and have been allocated to the operating segments as follows:



(In thousands)	OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	183,522	$	7,389	$	190,911

Intangible assets
Indefinite-lived	1,154,058		119,820		1,273,878
Finite-lived	94,772		26,167		120,939
	1,248,830		145,987		1,394,817

	$	1,432,352	$	153,376	$	1,585,728

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

+ Details

Gain on Settlement	12 Months Ended
Gain on Settlement	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Gain on Settlement	Gain on Settlement On June 15, 2011, we received a settlement payment of $8.0 million in the resolution of pending litigation, which Prestige Brands, Inc. had initiated for legal malpractice, breach of contract and breach of fiduciary duty against a law firm and two individual lawyers who had previously provided legal representation to Prestige Brands, Inc. Because the result of the litigation could only have resulted in a potential gain and the amount could not be determined prior to the settlement, the settlement payment was not disclosed prior to the actual receipt of the settlement. Additionally, the costs netted against the gain during the period ended June 30, 2011 were legal fees paid solely on a contingent basis and other immaterial legal fees incurred in the period ended June 30, 2011. All other costs and legal fees that were incurred prior to the period ended June 30, 2011 were immaterial and expensed as incurred. We incurred costs of $2.9 million in pursuing this matter. Therefore, we recorded a pre-tax gain on settlement of $5.1 million, net of costs incurred, and $3.2 million after income tax effects for the fiscal year ended March 31, 2012. The $5.1 million pre-tax gain is included in other (income) expense, as this gain did not relate to our ongoing operations.

Unaudited Quarterly Financial Information

12 Months Ended

Mar. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Unaudited Quarterly Financial Information

Unaudited quarterly financial information for 2014 and 2013 is as follows:

Year Ended March 31, 2014



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2013		September 30, 2013		December 31, 2013			March 31, 2014
Total revenues	$	142,971	$	168,442	$	146,212		$	144,256
Cost of sales (exclusive of depreciation shown below)	59,488		73,723		64,403			64,216
Gross profit	83,483		94,719		81,809			80,040

Operating expenses
Advertising and promotion	19,140		26,044		25,570			18,714
General and administrative	11,634		11,619		12,137			13,091
Depreciation and amortization	3,268		3,294		3,644			3,280
	34,042		40,957		41,351			35,085
Operating income	49,441		53,762		40,458			44,955
Net interest expense	15,905		16,439		21,260			14,978
Loss on extinguishment of debt	—		—		15,012			3,274
Income before income taxes	33,536		37,323		4,186			26,703
Provision for income taxes	12,844		4,531		1,056			10,702
Net income	20,692		32,792		3,130			16,001


Earnings per share:
Basic	$	0.40	$	0.64	$	0.06		$	0.31
Diluted	$	0.40	$	0.63	$	0.06		$	0.30

Weighted average shares outstanding:
Basic	51,222		51,463		51,806			51,893
Diluted	52,040		52,219		52,445			52,513

Comprehensive income, net of tax:
Currency translation adjustments	1		1,122		(2,694		)	2,414
Total other comprehensive income (loss)	1		1,122		(2,694		)	2,414
Comprehensive income	$	20,693	$	33,914	$	436		$	18,415

Year Ended March 31, 2013



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2012			September 30, 2012		December 31, 2012			March 31, 2013
Total revenues	$	146,997		$	161,855	$	160,232		$	154,513
Cost of sales (exclusive of depreciation shown below)	63,393			71,310		75,235			66,443
Gross profit	83,604			90,545		84,997			88,070

Operating expenses
Advertising and promotion	20,325			23,508		23,538			23,259
General and administrative	16,151			12,585		11,378			11,353
Depreciation and amortization	3,295			3,296		3,359			3,285
	39,771			39,389		38,275			37,897
Operating income	43,833			51,156		46,722			50,173
Net interest expense	19,848			19,660		26,661			18,238
Loss on extinguishment of debt	—			—		—			1,443
Income before income taxes	23,985			31,496		20,061			30,492
Provision for income taxes	9,330			12,252		7,804			11,143
Net income (loss)	14,655			19,244		12,257			19,349

Earnings per share:
Basic	$	0.29		$	0.38	$	0.24		$	0.38
Diluted	$	0.29		$	0.38	$	0.24		$	0.37

Weighted average shares outstanding:
Basic	50,342			50,364		50,686			51,147
Diluted	51,106			51,225		51,523			51,913

Comprehensive income, net of tax:
Currency translation adjustments	(42		)	66		(1		)	(114		)
Total other comprehensive income (loss)	(42		)	66		(1		)	(114		)
Comprehensive income	$	14,613		$	19,310	$	12,256		$	19,235

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References+ Details

Condensed Consolidating Financial Statements

12 Months Ended

Mar. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Financial Statements

As described in Note 10, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, have fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2013 Senior Notes and the 2012 Senior Notes, including, without limitation, the obligation to pay principal and interest with respect to the 2013 Senior Notes and the 2012 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2013 Senior Notes and the 2012 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, and Blacksmith Brands, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2013 Senior Notes and the 2012 Senior Notes. Although holders of the 2013 Senior Notes and the 2012 Senior Notes will be direct creditors of the guarantors of the 2013 Senior Notes and the 2012 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2013 Senior Notes or the 2012 Senior Notes and such subsidiaries will not be obligated with respect to the 2013 Senior Notes or the 2012 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2013 Senior Notes and the 2012 Senior Notes.

Presented below are supplemental Condensed Consolidating Balance Sheets as of March 31, 2014 and 2013 and Condensed Consolidating Income and Comprehensive Income Statements and Condensed Consolidating Statements of Cash Flows for each year in the three year period ended March 31, 2014. Such consolidating information includes separate columns for:

a) Prestige Brands Holdings, Inc., the parent,

b) Prestige Brands, Inc., the issuer,

c) Combined Subsidiary Guarantors,

d) Combined Non-Guarantor Subsidiaries, and

e) Elimination entries necessary to consolidate the Company and all of its subsidiaries.

The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this footnote should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Annual Report on Form 10-K for the fiscal year ended March 31, 2014.

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	98,278		$	478,069		$	23,286		$	(2,679	)	$	596,954
Other revenues	—			295			4,886			1,639			(1,893		)	4,927
Total Revenues	—			98,573			482,955			24,925			(4,572		)	601,881

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			37,272			218,692			9,428			(3,562		)	261,830
Gross profit	—			61,301			264,263			15,497			(1,010		)	340,051

Advertising and promotion	—			10,992			73,314			5,162			—			89,468
General and administrative	3,140			8,026			34,469			2,846			—			48,481
Depreciation and amortization	2,994			577			9,715			200			—			13,486
Total operating expenses	6,134			19,595			117,498			8,208			—			151,435

Operating income (loss)	(6,134		)	41,706			146,765			7,289			(1,010		)	188,616

Other (income) expense
Interest income	(48,730		)	(57,446		)	(2,327		)	(382		)	108,825			(60		)
Interest expense	34,436			68,642			72,064			2,325			(108,825		)	68,642
Loss on extinguishment of debt	—			18,286			—			—			—			18,286
Equity in income of subsidiaries	(66,739		)	(53,836		)	(4,052		)	—			124,627			—
Total other expense (income)	(81,033		)	(24,354		)	65,685			1,943			124,627			86,868

Income (loss) before income taxes	74,899			66,060			81,080			5,346			(125,637		)	101,748

Provision for income taxes	2,284			3,500			22,055			1,294			—			29,133
Net income (loss)	72,615			62,560			59,025			4,052			(125,637		)	72,615

Comprehensive income, net of tax:
Currency translation adjustments	843			843			843			843			(2,529		)	843
Total other comprehensive income (loss)	843			843			843			843			(2,529		)	843
Comprehensive income (loss)	$	73,458		$	63,403		$	59,868		$	4,895		$	(128,166	)	$	73,458

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	102,706		$	513,017		$	4,671		$	—		$	620,394
Other revenues	—			278			3,158			1,517			(1,750		)	3,203
Total Revenues	—			102,984			516,175			6,188			(1,750		)	623,597

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			39,333			236,795			2,003			(1,750		)	276,381
Gross profit	—			63,651			279,380			4,185			—			347,216

Advertising and promotion	—			12,605			76,599			1,426			—			90,630
General and administrative	5,127			6,917			38,713			710			—			51,467
Depreciation and amortization	1,346			569			11,261			59			—			13,235
Total operating expenses	6,473			20,091			126,573			2,195			—			155,332

Operating income (loss)	(6,473		)	43,560			152,807			1,990			—			191,884

Other (income) expense
Interest income	(30,561		)	(57,496		)	—			(1		)	88,045			(13		)
Interest expense	34,671			84,420			53,374			—			(88,045		)	84,420
Loss on extinguishment of debt	—			1,443			—			—			—			1,443
Equity in income of subsidiaries	(72,295		)	(65,784		)	(1,482		)	—			139,561			—
Total other expense (income)	(68,185		)	(37,417		)	51,892			(1		)	139,561			85,850

Income (loss) before income taxes	61,712			80,977			100,915			1,991			(139,561		)	106,034

Provision (benefit) for income taxes	(3,793		)	5,807			38,006			509			—			40,529
Net income (loss)	65,505			75,170			62,909			1,482			(139,561		)	65,505

Comprehensive income, net of tax:
Currency translation adjustments	(91		)	—			—			(91		)	91			(91		)
Total other comprehensive (loss) income	(91		)	—			—			(91		)	91			(91		)
Comprehensive income (loss)	$	65,414		$	75,170		$	62,909		$	1,391		$	(139,470	)	$	65,414

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2012



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	100,542		$	333,407		$	3,889		$	—		$	437,838
Other revenues	—			229			3,212			1,475			(1,669		)	3,247
Total Revenues	—			100,771			336,619			5,364			(1,669		)	441,085

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			36,658			177,112			1,600			(1,669		)	213,701
Gross profit	—			64,113			159,507			3,764			—			227,384

Advertising and promotion	—			11,918			43,906			1,303			—			57,127
General and administrative	17,181			10,059			28,698			762			—			56,700
Depreciation and amortization	538			570			9,556			70			—			10,734
Total operating expenses	17,719			22,547			82,160			2,135			—			124,561

Operating (loss) income	(17,719		)	41,566			77,347			1,629			—			102,823

Other (income) expense
Interest income	(50,357		)	(44,269		)	—			(221		)	94,829			(18		)
Interest expense	35,004			76,341			24,822			—			(94,829		)	41,338
Gain on settlement	(5,063		)	—			—			—			—			(5,063		)
Loss on extinguishment of debt	—			5,409			—			—			—			5,409
Equity in income of subsidiaries	(35,571		)	(37,192		)	(1,313		)	—			74,076			—
Total other expense (income)	(55,987		)	289			23,509			(221		)	74,076			41,666

Income (loss) before income taxes	38,268			41,277			53,838			1,850			(74,076		)	61,157

Provision for income taxes	1,056			1,599			20,565			725			—			23,945
Net income (loss)	37,212			39,678			33,273			1,125			(74,076		)	37,212

Comprehensive income, net of tax:
Currency translation adjustments	(13		)	—			—			13			(13		)	(13		)
Total other comprehensive (loss) income	(13		)	—			—			13			(13		)	(13		)
Comprehensive income	$	37,199		$	39,678		$	33,273		$	1,138		$	(74,089	)	$	37,199

Condensed Consolidating Balance Sheet

March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors		Combined Non- guarantor Subsidiaries		Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	24,644		$	—		$	—	$	3,687	$	—		$	28,331
Accounts receivable, net	473			14,245			45,885		4,447		—			65,050
Inventories	—			14,357			46,309		5,930		(1,010		)	65,586
Deferred income tax assets	260			925			4,914		445		—			6,544
Prepaid expenses and other current assets	8,004			113			2,898		659		—			11,674
Total current assets	33,381			29,640			100,006		15,168		(1,010		)	177,185

Property and equipment, net	8,966			112			226		293		—			9,597
Goodwill	—			66,007			101,540		23,364		—			190,911
Intangible assets, net	—			192,861			1,169,943		32,013		—			1,394,817
Other long-term assets	—			23,153			—		—		—			23,153
Intercompany receivable	655,146			1,824,482			656,759		13,595		(3,149,982		)	—
Investment in subsidiary	1,497,357			749,947			34,562		—		(2,281,866		)	—
Total Assets	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	4,416		$	7,658		$	33,553	$	2,659	$	—		$	48,286
Accrued interest payable	—			9,626			—		—		—			9,626
Other accrued liabilities	7,728			2,117			13,443		3,158		—			26,446
Total current liabilities	12,144			19,401			46,996		5,817		—			84,358

Long-term debt
Principal amount	—			937,500			—		—		—			937,500
Less unamortized discount	—			(3,086		)	—		—		—			(3,086		)
Long-term debt, net of unamortized discount	—			934,414			—		—		—			934,414

Deferred income tax liabilities	—			56,827			156,327		50		—			213,204
Other long-term liabilities	—			—			—		327		—			327
Intercompany payable	1,619,346			451,497			1,037,105		42,034		(3,149,982		)	—
Total Liabilities	1,631,490			1,462,139			1,240,428		48,228		(3,149,982		)	1,232,303

Stockholders' Equity
Common Stock	520			—			—		—		—			520
Additional paid-in capital	414,387			1,280,945			681,503		23,815		(1,986,263		)	414,387
Treasury stock, at cost - 206 shares	(1,431		)	—			—		—		—			(1,431		)
Accumulated other comprehensive income (loss), net of tax	739			739			739		739		(2,217		)	739
Retained earnings (accumulated deficit)	149,145			142,379			140,366		11,651		(294,396		)	149,145
Total Stockholders' Equity	563,360			1,424,063			822,608		36,205		(2,282,876		)	563,360
Total Liabilities and Stockholders' Equity	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663

Condensed Consolidating Balance Sheet

March 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors		Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	14,720		$	—		$	—	$	950		$	—		$	15,670
Accounts receivable, net	21			13,875			58,345		812			—			73,053
Inventories	—			11,164			48,474		563			—			60,201
Deferred income tax assets	218			855			5,276		—			—			6,349
Prepaid expenses and other current assets	4,942			93			3,609		256			—			8,900
Total current assets	19,901			25,987			115,704		2,581			—			164,173

Property and equipment, net	9,609			34			253		—			—			9,896
Goodwill	—			66,007			101,539		—			—			167,546
Intangible assets, net	—			193,396			1,179,524		320			—			1,373,240
Other long-term assets	—			24,944			—		—			—			24,944
Intercompany receivable	653,049			1,911,573			415,587		7,316			(2,987,525		)	—
Investment in subsidiary	1,429,775			638,611			7,067		—			(2,075,453		)	—
Total Assets	$	2,112,334		$	2,860,552		$	1,819,674	$	10,217		$	(5,062,978	)	$	1,739,799

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,601		$	10,600		$	37,695	$	480		$	—		$	51,376
Accrued interest payable	—			13,894			—		—			—			13,894
Other accrued liabilities	12,694			1,684			16,107		913			—			31,398
Total current liabilities	15,295			26,178			53,802		1,393			—			96,668

Long-term debt
Principal amount	—			978,000			—		—			—			978,000
Less unamortized discount	—			(7,100		)	—		—			—			(7,100		)
Long-term debt, net of unamortized discount	—			970,900			—		—			—			970,900

Deferred income tax liabilities	—			55,291			138,924		73			—			194,288
Intercompany payable	1,619,096			447,419			920,865		145			(2,987,525		)	—
Total Liabilities	1,634,391			1,499,788			1,113,591		1,611			(2,987,525		)	1,261,856

Stockholders' Equity
Preferred share rights	283			—			—		—			—			283
Common Stock	513			—			—		—			—			513
Additional paid-in capital	401,691			1,280,945			624,742		1,111			(1,906,798		)	401,691
Treasury stock, at cost - 181 shares	(687		)	—			—		—			—			(687		)
Accumulated other comprehensive (loss) income, net of tax	(104		)	—			—		(104		)	104			(104		)
Retained earnings (accumulated deficit)	76,247			79,819			81,341		7,599			(168,759		)	76,247
Total Stockholders' Equity	477,943			1,360,764			706,083		8,606			(2,075,453		)	477,943
Total Liabilities and Stockholders’ Equity	$	2,112,334		$	2,860,552		$	1,819,674	$	10,217		$	(5,062,978	)	$	1,739,799

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	72,615		$	62,560		$	59,025		$	4,052		$	(125,637	)	$	72,615
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	2,994			577			9,715			200			—			13,486
Deferred income taxes	(42		)	1,466			17,765			(177		)	—			19,012
Amortization of deferred financing costs	—			7,102			—			—			—			7,102
Stock-based compensation costs	5,146			—			—			—			—			5,146
Loss on extinguishment of debt	—			18,286			—			—			—			18,286
Premium payment of 2010 Senior notes	—			(15,527		)	—			—			—			(15,527		)
Amortization of debt discount	—			3,410			—			—			—			3,410
Gain on disposal of equipment	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(66,739		)	(53,836		)	(4,052		)	—			124,627			—
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(452		)	(370		)	12,460			(1,903		)	—			9,735
Inventories	—			(3,193		)	2,165			(2,832		)	1,010			(2,850		)
Prepaid expenses and other current assets	(3,062		)	(20		)	711			241			—			(2,130		)
Accounts payable	1,815			(2,942		)	(4,142		)	628			—			(4,641		)
Accrued liabilities	(4,966		)	(3,835		)	(2,664		)	(594		)	—			(12,059		)
Net cash provided by (used in) operating activities	7,309			13,678			90,980			(385		)	—			111,582

Investing Activities
Purchases of property and equipment	(2,351		)	(119		)	(108		)	(186		)	—			(2,764		)
Proceeds from the sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash (used in) provided by investing activities	(2,351		)	(55,334		)	(105		)	(186		)	—			(57,976		)

Financing Activities
Proceeds from issuance of 2013 Senior notes	—			400,000			—			—			—			400,000
Payment of 2010 Senior Notes	—			(250,000		)	—			—			—			(250,000		)
Repayment of 2012 Term Loan	—			(157,500		)	—			—			—			(157,500		)
Payment of deferred financing costs	—			(7,466		)	—			—			—			(7,466		)
Repayments under revolving credit facility	—			(83,000		)	—			—			—			(83,000		)
Borrowings under revolving credit facility	—			50,000			—			—			—			50,000
Proceeds from exercise of stock options	5,907			—			—			—			—			5,907
Excess tax benefits from share-based awards	1,650			—			—			—			—			1,650
Fair value of shares surrendered as payment of tax withholding	(744		)	—			—			—			—			(744		)
Intercompany activity, net	(1,847		)	89,622			(90,875		)	3,100			—			—
Net cash (used in) provided by financing activities	4,966			41,656			(90,875		)	3,100			—			(41,153		)

Effects of exchange rate changes on cash and cash equivalents	—			—			—			208			—			208
Increase in cash and cash equivalents	9,924			—			—			2,737			—			12,661
Cash and cash equivalents - beginning of year	14,720			—			—			950			—			15,670

Cash and cash equivalents - end of year	$	24,644		$	—		$	—		$	3,687		$	—		$	28,331

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	65,505		$	75,170		$	62,909		$	1,482		$	(139,561	)	$	65,505
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,346			569			11,261			59			—			13,235
Deferred income taxes	138			4,341			21,036			(10		)	—			25,505
Amortization of deferred financing costs	—			9,832			—			—			—			9,832
Stock-based compensation costs	3,772			—			—			—			—			3,772
Loss on extinguishment of debt	—			1,443			—			—			—			1,443
Amortization of debt discount	—			4,632			—			—			—			4,632
Lease termination costs	975			—			—			—			—			975
Loss on disposal of equipment	82			—			21			—			—			103
Equity in income of subsidiaries	(72,295		)	(65,784		)	(1,482		)	—			139,561			—
Changes in operating assets and liabilities
Accounts receivable	4			(373		)	(12,391		)	(122		)	—			(12,882		)
Inventories	—			(3,066		)	(6,360		)	84			—			(9,342		)
Prepaid expenses and other current assets	3,160			(37		)	(135		)	108			—			3,096
Accounts payable	(1,930		)	5,784			20,687			136			—			24,677
Accrued liabilities	(39		)	2			7,069			22			—			7,054
Net cash provided by operating activities	718			32,513			102,615			1,759			—			137,605

Investing Activities
Purchases of property and equipment	(10,268		)	—			—			—			—			(10,268		)
Proceeds from the sale of property and equipment	—			—			15			—			—			15
Proceeds from the sale of the Phazyme brand	—			—			21,700			—			—			21,700
Acquisition of brands from GSK purchase price adjustments	—			—			(226		)	—			—			(226		)
Intercompany activity, net	(226		)	—			226			—			—			—
Net cash provided by (used in) investing activities	(10,494		)	—			21,715			—			—			11,221

Financing Activities
Repayments of long-term debt	—			(190,000		)	—			—			—			(190,000		)
Repayments under revolving credit agreement	—			(15,000		)	—			—			—			(15,000		)
Borrowings under revolving credit agreement	—			48,000			—			—			—			48,000
Payment of deferred financing costs	—			(1,146		)	—			—			—			(1,146		)
Proceeds from exercise of stock options	6,029			—			—			—			—			6,029
Intercompany activity, net	246			125,633			(124,330		)	(1,549		)	—			—
Net cash (used in) provided by financing activities	6,275			(32,513		)	(124,330		)	(1,549		)	—			(152,117		)

Effect of exchange rate changes on cash and cash equivalents	—			—			—			(54		)	—			(54		)
(Decrease) increase in cash and cash equivalents	(3,501		)	—			—			156			—			(3,345		)
Cash and cash equivalents - beginning of year	18,221			—			—			794			—			19,015

Cash and cash equivalents - end of year	$	14,720		$	—		$	—		$	950		$	—		$	15,670

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2012



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	37,212		$	39,678		$	33,273		$	1,125		$	(74,076	)	$	37,212
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	538			570			9,556			70			—			10,734
Deferred income taxes	290			3,514			10,000			(11		)	—			13,793
Amortization of deferred financing costs	—			1,630			—			—			—			1,630
Stock-based compensation costs	3,078			—			—			—			—			3,078
Loss on extinguishment of debt	—			5,409			—			—			—			5,409
Amortization of debt discount	—			1,030			—			—			—			1,030
Equity in income of subsidiaries	(35,571		)	(37,192		)	(1,313		)	—			74,076			—
Changes in operating assets and liabilities
Accounts receivable	(12		)	(3,412		)	(12,367		)	(63		)	—			(15,854		)
Inventories	—			1,459			2,252			(1		)	—			3,710
Prepaid expenses and other current assets	(3,598		)	(20		)	968			(359		)	—			(3,009		)
Accounts payable	2,611			(1,598		)	4,139			(25		)	—			5,127
Accrued liabilities	417			2,984			856			335			—			4,592
Net cash provided by operating activities	4,965			14,052			47,364			1,071			—			67,452

Investing Activities
Purchases of equipment	(367		)	—			(239		)	—			—			(606		)
Proceeds from escrow of Blacksmith acquisition	—			—			1,200			—			—			1,200
Acquisition of GSK Brands	—			—			(662,800		)	—			—			(662,800		)
Intercompany activity, net	1,200			(662,800		)	661,600			—			—			—
Net cash (used in) provided by investing activities	833			(662,800		)	(239		)	—			—			(662,206		)

Financing Activities
Proceeds from issuance of 2012 Senior notes	—			250,000			—			—			—			250,000
Repayment of 2010 Senior Term Loan	—			(242,000		)	—			—			—			(242,000		)
Proceeds from issuance of 2012 Term Loan and 2010 Term Loan	—			650,100			—			—			—			650,100
Payment of deferred financing costs	—			(33,284		)	—			—			—			(33,284		)
Repayment of 2012 Term Loan	—			(25,000		)	—			—			—			(25,000		)
Proceeds from exercise of stock options	889			—			—			—			—			889
Shares surrendered as payment of tax withholding	(271		)	—			—			—			—			(271		)
Intercompany activity, net	(893		)	48,932			(47,125		)	(914		)	—			—
Net cash provided by (used in) financing activities	(275		)	648,748			(47,125		)	(914		)	—			600,434

Effect of exchange rate changes on cash and cash equivalents	—			—			—			1			—			1
Increase in cash	5,523			—			—			158			—			5,681
Cash and cash equivalents - beginning of year	12,698			—			—			636			—			13,334

Cash and cash equivalents - end of year	$	18,221		$	—		$	—		$	794		$	—		$	19,015

Subsequent Events	12 Months Ended
Subsequent Events	Mar. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Share based compensation: On May 12, 2014, the Compensation Committee of our Board of Directors granted 96,638 shares of restricted common stock units and stock options to acquire 307,490 shares of our common stock to certain executive officers and employees under the Plan. 75,638 shares of restricted common stock units vest in their entirety on the three-year anniversary of the date of grant and 21,000 shares of restricted common stock units vest 33.3% per year over three years. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $33.50 per share, which is equal to the closing price for our common stock on the day of the grant. Termination of employment prior to vesting will result in forfeiture of the restricted common stock units and the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan. Acquisition of Hydralyte: On April 30, 2014, we completed the acquisition of Hydralyte in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia. As of the date of this Annual Report on Form 10−K, we have not yet completed the initial accounting for the acquisition, and the acquisition date fair values of the acquired assets and assumed liabilities have not yet been determined. Hydralyte is the leading OTC brand in oral rehydration in Australia, and will be marketed and sold through Care Pharmaceuticals. Hydralyte is available in pharmacies in multiple forms and is indicated for oral rehydration following diarrhea, vomiting, fever, heat and ailments. We funded this acquisition with a combination of cash on the balance sheet and our existing credit facility. Acquisition of Insight Pharmaceuticals: On April 25, 2014, we announced that we had entered into a definitive agreement for the acquisition of Insight Pharmaceuticals Corporation, a marketer and distributor of feminine care and other OTC healthcare products for $750 million in cash. As of the date of this Annual Report on Form 10−K, we have not yet completed the initial accounting for the acquisition, and the acquisition date fair values of the acquired assets and assumed liabilities have not yet been determined. We anticipate closing on this transaction during the first half of this fiscal year, subject to customary closing conditions, including clearance under the Hart-Scott Rodino Antitrust Improvements Act of 1976. Financing for the transaction is expected from a combination of cash on the balance sheet, use of the 2012 ABL Revolver , and an add-on to our 2012 Term Loan.

Schedule II Valuation and Qualifying Accounts

12 Months Ended

Mar. 31, 2014

Valuation and Qualifying Accounts [Abstract]

Schedule II Valuation and Qualifying Accounts

VALUATION AND QUALIFYING ACCOUNTS



(In thousands)	Balance at Beginning of Year		Amounts Charged to Expense				Deductions			Other		Balance at End of Year
Year Ended March 31, 2014
Reserves for sales returns and allowance	$	6,446	$	38,314			$	(37,365	)	$	—	$	7,395
Reserves for trade promotions	8,523		39,967				(42,389		)	—		6,101
Reserves for consumer coupon redemptions	4,249		2,755				(5,262		)	—		1,742
Allowance for doubtful accounts	863		134				(6		)	44		1,035

Year Ended March 31, 2013
Reserves for sales returns and allowance	4,257		33,165				(30,976		)	—		6,446
Reserves for trade promotions	5,506		41,041				(38,024		)	—		8,523
Reserves for consumer coupon redemptions	3,509		8,282				(7,542		)	—		4,249
Allowance for doubtful accounts	604		265				(6		)	—		863

Year Ended March 31, 2012
Reserves for sales returns and allowance	6,208		23,457				(25,408		)	—		4,257
Reserves for trade promotions	4,853		32,185		(1	)	(31,532		)	—		5,506
Reserves for consumer coupon redemptions	2,723		7,180		(1	)	(6,394		)	—		3,509
Allowance for doubtful accounts	444		200				(40		)	—		604


(1)	We increased our reserves for Trade Promotion and Consumer Coupon Redemption by $3.0 million and $2.0 million, respectively, in an effort to gain market share for the PediaCare brand.

Business and Basis of Presentation (Policies)

12 Months Ended

Mar. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Use of Estimates

Cash and Cash Equivalents

Accounts Receivable

Inventories

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Goodwill

Intangible Assets

Deferred Financing Costs

Revenue Recognition

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.

Advertising and Promotion Costs

Stock-based Compensation

Income Taxes

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Recently Issued Accounting Standards

Business and Basis of Presentation (Tables)

12 Months Ended

Mar. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

Acquisitions (Tables)

12 Months Ended

Mar. 31, 2014

Business Acquisition [Line Items]

Pro Forma Information

This pro forma information is not necessarily indicative of either the combined results of operations that actually would have been realized by us had the acquisition of the GSK Brands been consummated at the beginning of the period for which the pro forma information is presented, or of future results.



	Year Ended March 31,
(In thousands, except per share data)	2012
	(Unaudited)
Revenues	$	616,849
Income from continuing operations	69,989

Basic earnings per share:
Income from continuing operations	$	1.39

Diluted earnings per share:
Income from continuing operations	$	1.38

Care Pharma

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.



(In thousands)	July 1, 2013

Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Deferred income tax assets	283
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,386

Accounts payable	1,537
Accrued expenses	2,788
Other long term liabilities	300
Total liabilities assumed	4,625

Net assets acquired	$	56,761

GSK Brands

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes our allocation of the $663.0 million purchase price to the assets we acquired on the GSK Brands acquisition dates:



(In thousands)	GSK Brands I (January 31, 2012)		GSK Brands II (March 30, 2012)		Total
Inventory	$	14,820	$	250	$	15,070
Prepaid expenses	3,575		—		3,575
Trade names	542,892		81,257		624,149
Goodwill	17,401		2,831		20,232
Total purchase price	$	578,688	$	84,338	$	663,026

Divestitures (Tables)

12 Months Ended

Mar. 31, 2014

Discontinued Operations and Disposal Groups [Abstract]

Assets Sold

The following table presents the assets sold at October 31, 2012 related to the Phazyme brand:



(In thousands)	October 31, 2012
Components of assets sold:
Inventory	$	220
Prepaid expenses	100
Trade names	15,604
Goodwill	6,382

- Definition

Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.

+ References+ Details

Goodwill (Tables)

12 Months Ended

Mar. 31, 2014

Goodwill [Abstract]

Summary of Changes in Goodwill

The following table summarizes the changes in the carrying value of goodwill by operating segment for each of 2012, 2013, and 2014:



(In thousands)	OTC Healthcare			Household Cleaning			Consolidated
Balance – March 31, 2011
Goodwill	$	277,677		$72,549			$350,226
Accumulated impairment losses	(130,170		)	(65,160		)	(195,330		)
Balance – March 31, 2011	147,507			7,389			154,896

2012 additions	20,006			—			20,006

Balance – March 31, 2012
Goodwill	296,483			72,549			369,032
Accumulated impairment losses	(130,170		)	(65,160		)	(195,330		)
Balance – March 31, 2012	166,313			7,389			173,702

2013 additions	226			—			226
2013 reductions	(6,382		)	—			(6,382		)

Balance – March 31, 2013
Goodwill	290,327			72,549			362,876
Accumulated impairment losses	(130,170		)	(65,160		)	(195,330		)
	160,157			7,389			167,546

2014 additions	23,122			—			23,122
Effects of foreign currency exchange rates	243			—			243

Balance – March 31, 2014
Goodwill	313,692			72,549			386,241
Accumulated impairment losses	(130,170		)	(65,160		)	(195,330		)
	$	183,522		$	7,389		$	190,911

Intangible Assets (Tables)

12 Months Ended

Mar. 31, 2014

Intangible Assets [Abstract]

Reconciliation of the Activity Affecting Intangible Assets

A reconciliation of the activity affecting intangible assets for each of 2012, 2013, and 2014 is as follows:



(In thousands)	Year Ended March 31, 2012
	Indefinite Lived Trademarks		Finite Lived Trademarks		Non Compete Agreement		Totals
Gross Amount
Balance – March 31, 2011 (including discontinued operations)	$	688,484	$	150,293	$	158	$	838,935
Additions	556,930		67,219		—		624,149
Disposals	—		—		—		—
Balance – March 31, 2012	$	1,245,414	$	217,512	$	158	$	1,463,084

Accumulated Amortization
Balance – March 31, 2011	$	—	$	52,416	$	158	$	52,574
Additions	—		9,988		—		9,988
Disposals	—		—		—		—
Balance – March 31, 2012	$	—	$	62,404	$	158	$	62,562

Intangibles, net – March 31, 2012	$	1,245,414	$	155,108	$	—	$	1,400,522



(In thousands)	Year Ended March 31, 2013
	Indefinite Lived Trademarks			Finite Lived Trademarks			Non Compete Agreement		Totals
Gross Amount
Balance – March 31, 2012	$	1,245,414		$	217,512		$	158	$	1,463,084
Reclassifications	(1,696		)	1,696			—		—
Reductions	—			(16,142		)	—		(16,142		)
Balance – March 31, 2013	$	1,243,718		$	203,066		$	158	$	1,446,942

Accumulated Amortization
Balance – March 31, 2012	$	—		$	62,404		$	158	$	62,562
Additions	—			11,678			—		11,678
Reductions	—			(538		)	—		(538		)
Balance – March 31, 2013	$	—		$	73,544		$	158	$	73,702

Intangibles, net – March 31, 2013	$	1,243,718		$	129,522		$	—	$	1,373,240



(In thousands)	Year Ended March 31, 2014
	Indefinite Lived Trademarks		Finite Lived Trademarks		Non Compete Agreement			Totals
Gross Amount
Balance – March 31, 2013	$	1,243,718	$	203,066	$	158		$	1,446,942
Additions	29,845		1,657		—			$	31,502
Reductions	—		—		(158		)	(158		)
Effects of foreign currency exchange rates	315		17		—			332
Balance – March 31, 2014	$	1,273,878	$	204,740	$	—		$	1,478,618

Accumulated Amortization
Balance – March 31, 2013	$	—	$	73,544	$	158		$	73,702
Additions	—		10,256		—			10,256
Reductions	—		—		(158		)	(158		)
Effects of foreign currency exchange rates	—		1		—			1
Balance – March 31, 2014	$	—	$	83,801	$	—		$	83,801

Intangibles, net – March 31, 2014	$	1,273,878	$	120,939	—			$	1,394,817

Schedule of Expected Amortization Expense

At March 31, 2014, finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 3 to 30 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):



Year Ending March 31,
2015	$	8,950
2016	8,950
2017	8,950
2018	8,950
2019	8,950
Thereafter	76,189
	$	120,939

Long-Term Debt (Tables)

12 Months Ended

Mar. 31, 2014

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	March 31,
	2014			2013
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year, commencing June 15, 2014. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	—
2012 Senior Notes bearing interest at 8.125%, with interest only payable on February 1st and August 1st of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
2012 Term Loan bearing interest at the Company's option at either a base rate plus applicable margin with a floor of 2.00% or LIBOR with a floor of 1.00%, due on January 31, 2019.	287,500			445,000
2012 ABL Revolver bearing interest at the Company's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	—			33,000
2010 Senior Notes bearing interest at 8.25%, with interest only payable on April 1st and October 1st of each year. The 2010 Senior Notes would have matured on April 1, 2018.	—			250,000
	937,500			978,000
Current portion of long-term debt	—			—
	937,500			978,000
Less: unamortized discount	(3,086		)	(7,100		)
Long-term debt, net of unamortized discount	$	934,414		$	970,900

Aggregate Future Principal Payments



Year Ending March 31,	Amount
2015	$	—
2016	—
2017	—
2018	—
2019	287,500
Thereafter	650,000
	$	937,500

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(e),(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Share-Based Compensation (Tables)

12 Months Ended

Mar. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Restricted Shares

A summary of the Company’s restricted shares granted under the Plan is presented below:



Restricted Shares	Shares (in thousands)		Weighted-Average Grant-Date Fair Value

Vested and Nonvested at March 31, 2011	275.4		$	8.46

Granted	217.5		11.81
Vested and issued	(103.4	)	9.93
Forfeited	(26.1	)	10.17
Vested and nonvested at March 31, 2012	363.4		9.92
Vested at March 31, 2012	54.0		7.40

Granted	128.9		13.59
Vested and issued	(58.7	)	9.99
Forfeited	(12.3	)	10.69
Vested and nonvested at March 31, 2013	421.3		11.01
Vested at March 31, 2013	70.4		8.52

Granted	126.6		30.19
Vested and issued	(104.8	)	9.98
Forfeited	(5.6	)	15.11
Vested and nonvested at March 31, 2014	437.5		16.76
Vested at March 31, 2014	69.6		9.34

Stock Options, Valuation Assumptions



	Year Ended March 31,
	2014		2013
Expected volatility	48.0	%	44.0	%
Expected dividends	—		—
Expected term in years	6		6.5
Risk-free rate	1.3	%	1.2	%

Stock Option Activity

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)

Outstanding at March 31, 2011	1,621.5		$	8.19

Granted	308.2		11.27
Exercised	(86.9	)	10.24
Forfeited or expired	(97.4	)	11.57
Outstanding at March 31, 2012	1,745.4		8.44

Granted	444.9		13.36
Exercised	(786.5	)	7.67
Forfeited or expired	(17.4	)	11.21
Outstanding at March 31, 2013	1,386.4		10.43

Granted	227.7		29.94
Exercised	(605.0	)	9.76
Forfeited or expired	(14.2	)	14.56
Outstanding at March 31, 2014	994.9		15.24		7.4	$	7,387
Exercisable at March 31, 2014	173.6		11.56		6.8	1,181

Income Taxes Income Taxes (Tables)

12 Months Ended

Mar. 31, 2014

Income Tax Disclosure [Abstract]

Components of Provision for Income Taxes

The provision for income taxes consists of the following:



(In thousands)	Year Ended March 31,
	2014			2013		2012
Current
Federal	$	7,801		$	12,520	$	8,127
State	625			1,972		1,396
Foreign	1,675			532		630
Deferred
Federal	27,045			23,845		13,100
State	(7,879		)	1,660		692
Foreign	(134		)	—		—
Total provision for income taxes	$	29,133		$	40,529	$	23,945

Components of Deferred Tax Balances

The principal components of our deferred tax balances are as follows:



(In thousands)	March 31,
	2014			2013
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$	4,082		$	2,807
Inventory capitalization	1,301			1,370
Inventory reserves	362			525
Net operating loss carryforwards	327			411
State income taxes	3,728			7,364
Accrued liabilities	642			1,896
Stock compensation	2,358			2,367
Other	702			496
Total deferred tax assets	13,502			17,236

Deferred Tax Liabilities
Property and equipment	(1,467		)	(1,504		)
Intangible assets	(218,696		)	(203,671		)
Total deferred tax liabilities	(220,163		)	(205,175		)

Net deferred tax liability	$	(206,661	)	$	(187,939	)

Reconciliation of Effective Tax Rate

A reconciliation of the effective tax rate compared to the statutory U.S. Federal tax rate is as follows:



	Year Ended March 31,
(In thousands)	2014					2013					2012
				%					%					%
Income tax provision at statutory rate	$	35,612		35.0		$	37,112		35.0		$	21,405		35.0
Foreign tax (benefit) provision	(918		)	(0.9	)	—			—		191			0.3
State income taxes, net of federal income tax benefit	2,004			2.0		3,413			3.2		2,073			3.4
Decrease in net deferred tax liability resulting from a change in the effective state tax rate	(8,892		)	(8.7	)	(1,741		)	(1.6	)	(1,177		)	(1.9	)
Nondeductible compensation	1,011			1.0		1,684			1.6		1,305			2.1
Other	316			0.3		61			—		148			0.3
Total provision for income taxes	29,133			28.7		40,529			38.2		23,945			39.2

Uncertain Tax Liability Activity

Uncertain tax liability activity is as follows:



	2014			2013
(In thousands)
Balance – beginning of year	$	1,016		292
Additions based on tax positions related to the current year	360			831
Reductions based on lapse of statute of limitations	(140		)	(107		)
Balance – end of year	$	1,236		$	1,016

- Definition

Tabular disclosure of tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of income tax contingencies, including: (1) the policy on classification of interest and penalties; (2) a tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period; the total amount(s) of: (3) unrecognized tax benefits that, if recognized, would affect the effective tax rate, and (4) interest and penalties recognized in each of the income statement and balance sheet; (5) for positions for which it is reasonably possible that the total amounts unrecognized will significantly change within 12 months of the reporting date the: (i) nature of the uncertainty, (ii) nature of the event that could occur that would cause the change, and (iii) an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made; and (6) a description of tax years that remain subject to examination by major tax jurisdictions.

+ References+ Details

Commitments and Contingencies (Tables)

12 Months Ended

Mar. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

The following summarizes future minimum lease payments for our operating leases:



(In thousands)	Facilities		Equipment		Total
Year Ending March 31,
2015	$	1,221	$	136	$	1,357
2016	994		135		1,129
2017	1,023		68		1,091
2018	1,044		—		1,044
2019	—		—		—
	$	4,282	$	339	$	4,621

Unrecorded Unconditional Purchase Obligations



(In thousands)
Year Ending March 31,
2015	1,105
2016	1,074
2017	1,044
2018	1,013
2019	982
Thereafter	560
	$	5,778

Business Segments (Tables)

12 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

Information about our Operating and Reportable Segments

The table below summarizes information about our operating and reportable segments.



	Year Ended March 31, 2014
	OTC Healthcare		Household Cleaning		Consolidated
(In thousands)
Net sales	$	513,056	$	83,898	$	596,954
Other revenues	791		4,136		4,927
Total revenues	513,847		88,034		601,881
Cost of sales	197,442		64,388		261,830
Gross profit	316,405		23,646		340,051
Advertising and promotion	86,578		2,890		89,468
Contribution margin	$	229,827	$	20,756	250,583
Other operating expenses					61,967
Operating income					188,616
Other expense					86,868
Income before income taxes					101,748
Provision for income taxes					29,133
Net income					$	72,615



	Year Ended March 31, 2013
	OTC Healthcare		Household Cleaning		Consolidated
(In thousands)
Net sales	$	536,247	$	84,147	$	620,394
Other revenues	684		2,519		3,203
Total revenues	536,931		86,666		623,597
Cost of sales	211,654		64,727		276,381
Gross profit	325,277		21,939		347,216
Advertising and promotion	84,537		6,093		90,630
Contribution margin	$	240,740	$	15,846	256,586
Other operating expenses					64,702
Operating income					191,884
Other expense					85,850
Income before income taxes					106,034
Provision for income taxes					40,529
Net income					$	65,505



	Year Ended March 31, 2012
	OTC Healthcare		Household Cleaning		Consolidated
(In thousands)
Net sales	$	344,282	$	93,556	$	437,838
Other revenues	719		2,528		3,247
Total revenues	345,001		96,084		441,085
Cost of sales	143,151		70,550		213,701
Gross profit	201,850		25,534		227,384
Advertising and promotion	51,895		5,232		57,127
Contribution margin	$	149,955	$	20,302	170,257
Other operating expenses					67,434
Operating income					102,823
Other expense					41,666
Income before income taxes					61,157
Provision for income taxes					23,945
Net income					$	37,212

Information about our Revenues from Similar Product Groups



	Year Ended March 31,
(In thousands)	2014		2013		2012
Analgesics	$	110,604	$	108,144	$	18,930
Cough & Cold	115,241		126,974		116,669
Gastrointestinal	83,971		97,940		29,489
Eye & Ear Care	86,390		86,380		74,363
Dermatologicals	52,363		52,401		52,592
Oral Care	48,774		49,617		46,551
Other OTC	16,504		15,475		6,407
Total OTC Healthcare Segment	513,847		536,931		345,001
Household Cleaning Segment	88,034		86,666		96,084
Consolidated Net Revenues	$	601,881	$	623,597	$	441,085

Allocation of Long-Term Assets to Segments

At March 31, 2014, substantially all of our long-term assets were located in the United States of America and have been allocated to the operating segments as follows:



(In thousands)	OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	183,522	$	7,389	$	190,911

Intangible assets
Indefinite-lived	1,154,058		119,820		1,273,878
Finite-lived	94,772		26,167		120,939
	1,248,830		145,987		1,394,817

	$	1,432,352	$	153,376	$	1,585,728

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details

Unaudited Quarterly Financial Information (Tables)

12 Months Ended

Mar. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

Unaudited quarterly financial information for 2014 and 2013 is as follows:

Year Ended March 31, 2014



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2013		September 30, 2013		December 31, 2013			March 31, 2014
Total revenues	$	142,971	$	168,442	$	146,212		$	144,256
Cost of sales (exclusive of depreciation shown below)	59,488		73,723		64,403			64,216
Gross profit	83,483		94,719		81,809			80,040

Operating expenses
Advertising and promotion	19,140		26,044		25,570			18,714
General and administrative	11,634		11,619		12,137			13,091
Depreciation and amortization	3,268		3,294		3,644			3,280
	34,042		40,957		41,351			35,085
Operating income	49,441		53,762		40,458			44,955
Net interest expense	15,905		16,439		21,260			14,978
Loss on extinguishment of debt	—		—		15,012			3,274
Income before income taxes	33,536		37,323		4,186			26,703
Provision for income taxes	12,844		4,531		1,056			10,702
Net income	20,692		32,792		3,130			16,001


Earnings per share:
Basic	$	0.40	$	0.64	$	0.06		$	0.31
Diluted	$	0.40	$	0.63	$	0.06		$	0.30

Weighted average shares outstanding:
Basic	51,222		51,463		51,806			51,893
Diluted	52,040		52,219		52,445			52,513

Comprehensive income, net of tax:
Currency translation adjustments	1		1,122		(2,694		)	2,414
Total other comprehensive income (loss)	1		1,122		(2,694		)	2,414
Comprehensive income	$	20,693	$	33,914	$	436		$	18,415

Year Ended March 31, 2013



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2012			September 30, 2012		December 31, 2012			March 31, 2013
Total revenues	$	146,997		$	161,855	$	160,232		$	154,513
Cost of sales (exclusive of depreciation shown below)	63,393			71,310		75,235			66,443
Gross profit	83,604			90,545		84,997			88,070

Operating expenses
Advertising and promotion	20,325			23,508		23,538			23,259
General and administrative	16,151			12,585		11,378			11,353
Depreciation and amortization	3,295			3,296		3,359			3,285
	39,771			39,389		38,275			37,897
Operating income	43,833			51,156		46,722			50,173
Net interest expense	19,848			19,660		26,661			18,238
Loss on extinguishment of debt	—			—		—			1,443
Income before income taxes	23,985			31,496		20,061			30,492
Provision for income taxes	9,330			12,252		7,804			11,143
Net income (loss)	14,655			19,244		12,257			19,349

Earnings per share:
Basic	$	0.29		$	0.38	$	0.24		$	0.38
Diluted	$	0.29		$	0.38	$	0.24		$	0.37

Weighted average shares outstanding:
Basic	50,342			50,364		50,686			51,147
Diluted	51,106			51,225		51,523			51,913

Comprehensive income, net of tax:
Currency translation adjustments	(42		)	66		(1		)	(114		)
Total other comprehensive income (loss)	(42		)	66		(1		)	(114		)
Comprehensive income	$	14,613		$	19,310	$	12,256		$	19,235

Condensed Consolidating Financial Statements (Tables)

12 Months Ended

Mar. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Statements of Income and Comprehensive Income

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	98,278		$	478,069		$	23,286		$	(2,679	)	$	596,954
Other revenues	—			295			4,886			1,639			(1,893		)	4,927
Total Revenues	—			98,573			482,955			24,925			(4,572		)	601,881

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			37,272			218,692			9,428			(3,562		)	261,830
Gross profit	—			61,301			264,263			15,497			(1,010		)	340,051

Advertising and promotion	—			10,992			73,314			5,162			—			89,468
General and administrative	3,140			8,026			34,469			2,846			—			48,481
Depreciation and amortization	2,994			577			9,715			200			—			13,486
Total operating expenses	6,134			19,595			117,498			8,208			—			151,435

Operating income (loss)	(6,134		)	41,706			146,765			7,289			(1,010		)	188,616

Other (income) expense
Interest income	(48,730		)	(57,446		)	(2,327		)	(382		)	108,825			(60		)
Interest expense	34,436			68,642			72,064			2,325			(108,825		)	68,642
Loss on extinguishment of debt	—			18,286			—			—			—			18,286
Equity in income of subsidiaries	(66,739		)	(53,836		)	(4,052		)	—			124,627			—
Total other expense (income)	(81,033		)	(24,354		)	65,685			1,943			124,627			86,868

Income (loss) before income taxes	74,899			66,060			81,080			5,346			(125,637		)	101,748

Provision for income taxes	2,284			3,500			22,055			1,294			—			29,133
Net income (loss)	72,615			62,560			59,025			4,052			(125,637		)	72,615

Comprehensive income, net of tax:
Currency translation adjustments	843			843			843			843			(2,529		)	843
Total other comprehensive income (loss)	843			843			843			843			(2,529		)	843
Comprehensive income (loss)	$	73,458		$	63,403		$	59,868		$	4,895		$	(128,166	)	$	73,458

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	102,706		$	513,017		$	4,671		$	—		$	620,394
Other revenues	—			278			3,158			1,517			(1,750		)	3,203
Total Revenues	—			102,984			516,175			6,188			(1,750		)	623,597

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			39,333			236,795			2,003			(1,750		)	276,381
Gross profit	—			63,651			279,380			4,185			—			347,216

Advertising and promotion	—			12,605			76,599			1,426			—			90,630
General and administrative	5,127			6,917			38,713			710			—			51,467
Depreciation and amortization	1,346			569			11,261			59			—			13,235
Total operating expenses	6,473			20,091			126,573			2,195			—			155,332

Operating income (loss)	(6,473		)	43,560			152,807			1,990			—			191,884

Other (income) expense
Interest income	(30,561		)	(57,496		)	—			(1		)	88,045			(13		)
Interest expense	34,671			84,420			53,374			—			(88,045		)	84,420
Loss on extinguishment of debt	—			1,443			—			—			—			1,443
Equity in income of subsidiaries	(72,295		)	(65,784		)	(1,482		)	—			139,561			—
Total other expense (income)	(68,185		)	(37,417		)	51,892			(1		)	139,561			85,850

Income (loss) before income taxes	61,712			80,977			100,915			1,991			(139,561		)	106,034

Provision (benefit) for income taxes	(3,793		)	5,807			38,006			509			—			40,529
Net income (loss)	65,505			75,170			62,909			1,482			(139,561		)	65,505

Comprehensive income, net of tax:
Currency translation adjustments	(91		)	—			—			(91		)	91			(91		)
Total other comprehensive (loss) income	(91		)	—			—			(91		)	91			(91		)
Comprehensive income (loss)	$	65,414		$	75,170		$	62,909		$	1,391		$	(139,470	)	$	65,414

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2012



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	100,542		$	333,407		$	3,889		$	—		$	437,838
Other revenues	—			229			3,212			1,475			(1,669		)	3,247
Total Revenues	—			100,771			336,619			5,364			(1,669		)	441,085

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			36,658			177,112			1,600			(1,669		)	213,701
Gross profit	—			64,113			159,507			3,764			—			227,384

Advertising and promotion	—			11,918			43,906			1,303			—			57,127
General and administrative	17,181			10,059			28,698			762			—			56,700
Depreciation and amortization	538			570			9,556			70			—			10,734
Total operating expenses	17,719			22,547			82,160			2,135			—			124,561

Operating (loss) income	(17,719		)	41,566			77,347			1,629			—			102,823

Other (income) expense
Interest income	(50,357		)	(44,269		)	—			(221		)	94,829			(18		)
Interest expense	35,004			76,341			24,822			—			(94,829		)	41,338
Gain on settlement	(5,063		)	—			—			—			—			(5,063		)
Loss on extinguishment of debt	—			5,409			—			—			—			5,409
Equity in income of subsidiaries	(35,571		)	(37,192		)	(1,313		)	—			74,076			—
Total other expense (income)	(55,987		)	289			23,509			(221		)	74,076			41,666

Income (loss) before income taxes	38,268			41,277			53,838			1,850			(74,076		)	61,157

Provision for income taxes	1,056			1,599			20,565			725			—			23,945
Net income (loss)	37,212			39,678			33,273			1,125			(74,076		)	37,212

Comprehensive income, net of tax:
Currency translation adjustments	(13		)	—			—			13			(13		)	(13		)
Total other comprehensive (loss) income	(13		)	—			—			13			(13		)	(13		)
Comprehensive income	$	37,199		$	39,678		$	33,273		$	1,138		$	(74,089	)	$	37,199

Condensed Consolidating Balance Sheet

March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors		Combined Non- guarantor Subsidiaries		Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	24,644		$	—		$	—	$	3,687	$	—		$	28,331
Accounts receivable, net	473			14,245			45,885		4,447		—			65,050
Inventories	—			14,357			46,309		5,930		(1,010		)	65,586
Deferred income tax assets	260			925			4,914		445		—			6,544
Prepaid expenses and other current assets	8,004			113			2,898		659		—			11,674
Total current assets	33,381			29,640			100,006		15,168		(1,010		)	177,185

Property and equipment, net	8,966			112			226		293		—			9,597
Goodwill	—			66,007			101,540		23,364		—			190,911
Intangible assets, net	—			192,861			1,169,943		32,013		—			1,394,817
Other long-term assets	—			23,153			—		—		—			23,153
Intercompany receivable	655,146			1,824,482			656,759		13,595		(3,149,982		)	—
Investment in subsidiary	1,497,357			749,947			34,562		—		(2,281,866		)	—
Total Assets	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	4,416		$	7,658		$	33,553	$	2,659	$	—		$	48,286
Accrued interest payable	—			9,626			—		—		—			9,626
Other accrued liabilities	7,728			2,117			13,443		3,158		—			26,446
Total current liabilities	12,144			19,401			46,996		5,817		—			84,358

Long-term debt
Principal amount	—			937,500			—		—		—			937,500
Less unamortized discount	—			(3,086		)	—		—		—			(3,086		)
Long-term debt, net of unamortized discount	—			934,414			—		—		—			934,414

Deferred income tax liabilities	—			56,827			156,327		50		—			213,204
Other long-term liabilities	—			—			—		327		—			327
Intercompany payable	1,619,346			451,497			1,037,105		42,034		(3,149,982		)	—
Total Liabilities	1,631,490			1,462,139			1,240,428		48,228		(3,149,982		)	1,232,303

Stockholders' Equity
Common Stock	520			—			—		—		—			520
Additional paid-in capital	414,387			1,280,945			681,503		23,815		(1,986,263		)	414,387
Treasury stock, at cost - 206 shares	(1,431		)	—			—		—		—			(1,431		)
Accumulated other comprehensive income (loss), net of tax	739			739			739		739		(2,217		)	739
Retained earnings (accumulated deficit)	149,145			142,379			140,366		11,651		(294,396		)	149,145
Total Stockholders' Equity	563,360			1,424,063			822,608		36,205		(2,282,876		)	563,360
Total Liabilities and Stockholders' Equity	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663

Condensed Consolidating Balance Sheet

March 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors		Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	14,720		$	—		$	—	$	950		$	—		$	15,670
Accounts receivable, net	21			13,875			58,345		812			—			73,053
Inventories	—			11,164			48,474		563			—			60,201
Deferred income tax assets	218			855			5,276		—			—			6,349
Prepaid expenses and other current assets	4,942			93			3,609		256			—			8,900
Total current assets	19,901			25,987			115,704		2,581			—			164,173

Property and equipment, net	9,609			34			253		—			—			9,896
Goodwill	—			66,007			101,539		—			—			167,546
Intangible assets, net	—			193,396			1,179,524		320			—			1,373,240
Other long-term assets	—			24,944			—		—			—			24,944
Intercompany receivable	653,049			1,911,573			415,587		7,316			(2,987,525		)	—
Investment in subsidiary	1,429,775			638,611			7,067		—			(2,075,453		)	—
Total Assets	$	2,112,334		$	2,860,552		$	1,819,674	$	10,217		$	(5,062,978	)	$	1,739,799

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,601		$	10,600		$	37,695	$	480		$	—		$	51,376
Accrued interest payable	—			13,894			—		—			—			13,894
Other accrued liabilities	12,694			1,684			16,107		913			—			31,398
Total current liabilities	15,295			26,178			53,802		1,393			—			96,668

Long-term debt
Principal amount	—			978,000			—		—			—			978,000
Less unamortized discount	—			(7,100		)	—		—			—			(7,100		)
Long-term debt, net of unamortized discount	—			970,900			—		—			—			970,900

Deferred income tax liabilities	—			55,291			138,924		73			—			194,288
Intercompany payable	1,619,096			447,419			920,865		145			(2,987,525		)	—
Total Liabilities	1,634,391			1,499,788			1,113,591		1,611			(2,987,525		)	1,261,856

Stockholders' Equity
Preferred share rights	283			—			—		—			—			283
Common Stock	513			—			—		—			—			513
Additional paid-in capital	401,691			1,280,945			624,742		1,111			(1,906,798		)	401,691
Treasury stock, at cost - 181 shares	(687		)	—			—		—			—			(687		)
Accumulated other comprehensive (loss) income, net of tax	(104		)	—			—		(104		)	104			(104		)
Retained earnings (accumulated deficit)	76,247			79,819			81,341		7,599			(168,759		)	76,247
Total Stockholders' Equity	477,943			1,360,764			706,083		8,606			(2,075,453		)	477,943
Total Liabilities and Stockholders’ Equity	$	2,112,334		$	2,860,552		$	1,819,674	$	10,217		$	(5,062,978	)	$	1,739,799

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	72,615		$	62,560		$	59,025		$	4,052		$	(125,637	)	$	72,615
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	2,994			577			9,715			200			—			13,486
Deferred income taxes	(42		)	1,466			17,765			(177		)	—			19,012
Amortization of deferred financing costs	—			7,102			—			—			—			7,102
Stock-based compensation costs	5,146			—			—			—			—			5,146
Loss on extinguishment of debt	—			18,286			—			—			—			18,286
Premium payment of 2010 Senior notes	—			(15,527		)	—			—			—			(15,527		)
Amortization of debt discount	—			3,410			—			—			—			3,410
Gain on disposal of equipment	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(66,739		)	(53,836		)	(4,052		)	—			124,627			—
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(452		)	(370		)	12,460			(1,903		)	—			9,735
Inventories	—			(3,193		)	2,165			(2,832		)	1,010			(2,850		)
Prepaid expenses and other current assets	(3,062		)	(20		)	711			241			—			(2,130		)
Accounts payable	1,815			(2,942		)	(4,142		)	628			—			(4,641		)
Accrued liabilities	(4,966		)	(3,835		)	(2,664		)	(594		)	—			(12,059		)
Net cash provided by (used in) operating activities	7,309			13,678			90,980			(385		)	—			111,582

Investing Activities
Purchases of property and equipment	(2,351		)	(119		)	(108		)	(186		)	—			(2,764		)
Proceeds from the sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash (used in) provided by investing activities	(2,351		)	(55,334		)	(105		)	(186		)	—			(57,976		)

Financing Activities
Proceeds from issuance of 2013 Senior notes	—			400,000			—			—			—			400,000
Payment of 2010 Senior Notes	—			(250,000		)	—			—			—			(250,000		)
Repayment of 2012 Term Loan	—			(157,500		)	—			—			—			(157,500		)
Payment of deferred financing costs	—			(7,466		)	—			—			—			(7,466		)
Repayments under revolving credit facility	—			(83,000		)	—			—			—			(83,000		)
Borrowings under revolving credit facility	—			50,000			—			—			—			50,000
Proceeds from exercise of stock options	5,907			—			—			—			—			5,907
Excess tax benefits from share-based awards	1,650			—			—			—			—			1,650
Fair value of shares surrendered as payment of tax withholding	(744		)	—			—			—			—			(744		)
Intercompany activity, net	(1,847		)	89,622			(90,875		)	3,100			—			—
Net cash (used in) provided by financing activities	4,966			41,656			(90,875		)	3,100			—			(41,153		)

Effects of exchange rate changes on cash and cash equivalents	—			—			—			208			—			208
Increase in cash and cash equivalents	9,924			—			—			2,737			—			12,661
Cash and cash equivalents - beginning of year	14,720			—			—			950			—			15,670

Cash and cash equivalents - end of year	$	24,644		$	—		$	—		$	3,687		$	—		$	28,331

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	65,505		$	75,170		$	62,909		$	1,482		$	(139,561	)	$	65,505
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,346			569			11,261			59			—			13,235
Deferred income taxes	138			4,341			21,036			(10		)	—			25,505
Amortization of deferred financing costs	—			9,832			—			—			—			9,832
Stock-based compensation costs	3,772			—			—			—			—			3,772
Loss on extinguishment of debt	—			1,443			—			—			—			1,443
Amortization of debt discount	—			4,632			—			—			—			4,632
Lease termination costs	975			—			—			—			—			975
Loss on disposal of equipment	82			—			21			—			—			103
Equity in income of subsidiaries	(72,295		)	(65,784		)	(1,482		)	—			139,561			—
Changes in operating assets and liabilities
Accounts receivable	4			(373		)	(12,391		)	(122		)	—			(12,882		)
Inventories	—			(3,066		)	(6,360		)	84			—			(9,342		)
Prepaid expenses and other current assets	3,160			(37		)	(135		)	108			—			3,096
Accounts payable	(1,930		)	5,784			20,687			136			—			24,677
Accrued liabilities	(39		)	2			7,069			22			—			7,054
Net cash provided by operating activities	718			32,513			102,615			1,759			—			137,605

Investing Activities
Purchases of property and equipment	(10,268		)	—			—			—			—			(10,268		)
Proceeds from the sale of property and equipment	—			—			15			—			—			15
Proceeds from the sale of the Phazyme brand	—			—			21,700			—			—			21,700
Acquisition of brands from GSK purchase price adjustments	—			—			(226		)	—			—			(226		)
Intercompany activity, net	(226		)	—			226			—			—			—
Net cash provided by (used in) investing activities	(10,494		)	—			21,715			—			—			11,221

Financing Activities
Repayments of long-term debt	—			(190,000		)	—			—			—			(190,000		)
Repayments under revolving credit agreement	—			(15,000		)	—			—			—			(15,000		)
Borrowings under revolving credit agreement	—			48,000			—			—			—			48,000
Payment of deferred financing costs	—			(1,146		)	—			—			—			(1,146		)
Proceeds from exercise of stock options	6,029			—			—			—			—			6,029
Intercompany activity, net	246			125,633			(124,330		)	(1,549		)	—			—
Net cash (used in) provided by financing activities	6,275			(32,513		)	(124,330		)	(1,549		)	—			(152,117		)

Effect of exchange rate changes on cash and cash equivalents	—			—			—			(54		)	—			(54		)
(Decrease) increase in cash and cash equivalents	(3,501		)	—			—			156			—			(3,345		)
Cash and cash equivalents - beginning of year	18,221			—			—			794			—			19,015

Cash and cash equivalents - end of year	$	14,720		$	—		$	—		$	950		$	—		$	15,670

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2012



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	37,212		$	39,678		$	33,273		$	1,125		$	(74,076	)	$	37,212
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	538			570			9,556			70			—			10,734
Deferred income taxes	290			3,514			10,000			(11		)	—			13,793
Amortization of deferred financing costs	—			1,630			—			—			—			1,630
Stock-based compensation costs	3,078			—			—			—			—			3,078
Loss on extinguishment of debt	—			5,409			—			—			—			5,409
Amortization of debt discount	—			1,030			—			—			—			1,030
Equity in income of subsidiaries	(35,571		)	(37,192		)	(1,313		)	—			74,076			—
Changes in operating assets and liabilities
Accounts receivable	(12		)	(3,412		)	(12,367		)	(63		)	—			(15,854		)
Inventories	—			1,459			2,252			(1		)	—			3,710
Prepaid expenses and other current assets	(3,598		)	(20		)	968			(359		)	—			(3,009		)
Accounts payable	2,611			(1,598		)	4,139			(25		)	—			5,127
Accrued liabilities	417			2,984			856			335			—			4,592
Net cash provided by operating activities	4,965			14,052			47,364			1,071			—			67,452

Investing Activities
Purchases of equipment	(367		)	—			(239		)	—			—			(606		)
Proceeds from escrow of Blacksmith acquisition	—			—			1,200			—			—			1,200
Acquisition of GSK Brands	—			—			(662,800		)	—			—			(662,800		)
Intercompany activity, net	1,200			(662,800		)	661,600			—			—			—
Net cash (used in) provided by investing activities	833			(662,800		)	(239		)	—			—			(662,206		)

Financing Activities
Proceeds from issuance of 2012 Senior notes	—			250,000			—			—			—			250,000
Repayment of 2010 Senior Term Loan	—			(242,000		)	—			—			—			(242,000		)
Proceeds from issuance of 2012 Term Loan and 2010 Term Loan	—			650,100			—			—			—			650,100
Payment of deferred financing costs	—			(33,284		)	—			—			—			(33,284		)
Repayment of 2012 Term Loan	—			(25,000		)	—			—			—			(25,000		)
Proceeds from exercise of stock options	889			—			—			—			—			889
Shares surrendered as payment of tax withholding	(271		)	—			—			—			—			(271		)
Intercompany activity, net	(893		)	48,932			(47,125		)	(914		)	—			—
Net cash provided by (used in) financing activities	(275		)	648,748			(47,125		)	(914		)	—			600,434

Effect of exchange rate changes on cash and cash equivalents	—			—			—			1			—			1
Increase in cash	5,523			—			—			158			—			5,681
Cash and cash equivalents - beginning of year	12,698			—			—			636			—			13,334

Cash and cash equivalents - end of year	$	18,221		$	—		$	—		$	794		$	—		$	19,015

Business and Basis of Presentation (Cost of Sales) (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Shipping, warehousing and handling costs	$ 32.0	$ 30.6	$ 27.8

- Definition

Cost incurred during the reporting period in transporting goods and services to customers. Includes freight-out costs.

+ References+ Details

Acquisitions (Care Pharmaceuticals Pty Ltd.) (Details) (USD $)	12 Months Ended				12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2014 Care Pharma	Jul. 02, 2013 Care Pharma
Purchase Price
Cash acquired						$ 1,546,000
Accounts receivable						1,658,000
Inventories						2,465,000
Deferred income tax assets						283,000
Prepaids and other current assets						647,000
Property, plant and equipment						163,000
Goodwill	190,911,000	167,546,000	173,702,000	154,896,000		23,122,000
Intangible assets						31,502,000
Total assets acquired						61,386,000
Accounts payable						1,537,000
Accrued expenses						2,788,000
Other long term liabilities						300,000
Total liabilities assumed						4,625,000
Net assets acquired						56,761,000
Indefinite-lived intangible assets						29,800,000
Finite-lived intangibles						1,700,000
Purchased amortizable intangible assets, weighted average useful life		19 years 3 months 18 days			15 years 1 month 6 days
Amortizable intangible assets, weighted average remaining life	13 years 6 months 0 days				14 years 6 months 0 days
Goodwill acquired during period	$ 23,122,000	$ 226,000	$ 20,006,000

Acquisitions (Acquisition of GlaxoSmithKline OTC Brands) (Details) (USD $)	9 Months Ended	12 Months Ended				2 Months Ended	12 Months Ended			0 Months Ended		0 Months Ended	1 Months Ended	0 Months Ended		12 Months Ended
	Dec. 31, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2011	May 31, 2012 GSK Brands	Mar. 31, 2014 GSK Brands	Mar. 31, 2013 GSK Brands	Dec. 20, 2011 GSK Brands agreement brand	Dec. 20, 2011 GSK	Mar. 31, 2014 GSK	Jan. 31, 2012 GSK Brands I brand	Apr. 30, 2012 GSK Brands I	Mar. 30, 2012 GSK Brands II	Mar. 30, 2012 GSK	Mar. 31, 2013 GSK
Business Acquisition [Line Items]
Number of purchase agreements									2
Number of brands acquired									17			15
Purchase price, gross										$ 660,000,000		$ 615,000,000		$ 45,000,000
Post-closing adjustments added to purchase price	200,000	0	226,000	0		3,000,000							2,800,000
Transitional services agreement, estimated monthly costs to be incurred															2,500,000
Transitional services agreement, actual costs incurred																6,900,000
Goodwill, expected tax deductible amount											20,200,000
Trademark, nonamortizable											556,900,000
Purchased amortizable intangible assets, weighted average useful life			19 years 3 months 18 days
Amortizable intangible assets, weighted average remaining life		13 years 6 months 0 days						17 years
Revenue of acquiree since acquisition date, actual								211,200,000
Net income of acquiree since acquisition date, actual								27,400,000
Purchase Price
Inventories								15,070,000				14,820,000		250,000
Prepaids and other current assets								3,575,000				3,575,000		0
Amortizable intangible assets								624,149,000			67,200,000	542,892,000		81,257,000
Goodwill		190,911,000	167,546,000	173,702,000	154,896,000			20,232,000				17,401,000		2,831,000
Purchase price								663,026,000				578,688,000		84,338,000
Pro Forma Information
Revenues							616,849,000
Income from continuing operations							$ 69,989,000
Basic earnings per share Income from continuing operations (USD per share)							$ 1.39
Diluted earnings per share Income from continuing operations (USD per share)							$ 1.38

Divestitures (Details) (Phazyme, USD $) In Thousands, unless otherwise specified	Oct. 31, 2012
Phazyme
Components of assets sold:
Inventory	$ 220
Prepaid expenses	100
Trade names	15,604
Goodwill	$ 6,382

Accounts Receivable (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 74,992	$ 80,361
Less allowances for discounts, returns and uncollectible accounts	(9,942)	(7,308)
Accounts receivable, net	65,050	73,053
Trade Accounts Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	73,632	79,746
Other Receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 1,360	$ 615

Inventories (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 3,099,000	$ 1,875,000
Finished goods	62,487,000	58,326,000
Inventories	65,586,000	60,201,000
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 1,100,000	$ 1,300,000

- Definition

Amount of valuation reserve for inventory.

+ References+ Details

Property and Equipment (Details) (USD $)	12 Months Ended
Property and Equipment (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Components of Property and Equipment
Property and equipment, gross	$ 17,442,000	$ 14,362,000
Accumulated depreciation	(7,845,000)	(4,466,000)
Property and equipment, net	9,597,000	9,896,000
Depreciation	3,200,000	1,600,000	700,000
Machinery
Components of Property and Equipment
Property and equipment, gross	1,927,000	1,580,000
Computer Equipment
Components of Property and Equipment
Property and equipment, gross	8,923,000	6,559,000
Furniture and Fixtures
Components of Property and Equipment
Property and equipment, gross	1,858,000	1,510,000
Leasehold Improvements
Components of Property and Equipment
Property and equipment, gross	4,734,000	4,713,000
Impairment of assets	$ 100,000

- Definition

The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).

+ References+ Details

Goodwill (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Goodwill [Roll Forward]
Goodwill, gross, beginning	$ 362,876	$ 369,032	$ 350,226
Accumulated impairment losses, beginning	(195,330)	(195,330)	(195,330)
Goodwill, net, beginning	167,546	173,702	154,896
Additions	23,122	226	20,006
Reductions		(6,382)
Effects of foreign currency exchange rates	243
Goodwill, gross, ending	386,241	362,876	369,032
Accumulated impairment losses, ending	(195,330)	(195,330)	(195,330)
Goodwill, net, ending	190,911	167,546	173,702
OTC Healthcare
Goodwill [Roll Forward]
Goodwill, gross, beginning	290,327	296,483	277,677
Accumulated impairment losses, beginning	(130,170)	(130,170)	(130,170)
Goodwill, net, beginning	160,157	166,313	147,507
Additions	23,122	226	20,006
Reductions		(6,382)
Effects of foreign currency exchange rates	243
Goodwill, gross, ending	313,692	290,327	296,483
Accumulated impairment losses, ending	(130,170)	(130,170)	(130,170)
Goodwill, net, ending	183,522	160,157	166,313
Household Cleaning
Goodwill [Roll Forward]
Goodwill, gross, beginning	72,549	72,549	72,549
Accumulated impairment losses, beginning	(65,160)	(65,160)	(65,160)
Goodwill, net, beginning	7,389	7,389	7,389
Additions	0	0	0
Reductions		0
Effects of foreign currency exchange rates	0
Goodwill, gross, ending	72,549	72,549	72,549
Accumulated impairment losses, ending	(65,160)	(65,160)	(65,160)
Goodwill, net, ending	$ 7,389	$ 7,389	$ 7,389

Goodwill (Narrative) (Details) (USD $)	12 Months Ended				3 Months Ended		0 Months Ended			9 Months Ended
Goodwill (Narrative) (Details) (USD $)	Mar. 31, 2014 unit	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2011	Jun. 30, 2013 GSK Brands	Mar. 31, 2013 GSK Brands	Jan. 31, 2012 GSK Brands I	Mar. 30, 2012 GSK Brands II	Jul. 02, 2013 Care Pharma	Dec. 31, 2012 Phazyme	Oct. 31, 2012 Phazyme	Mar. 31, 2014 Reporting Unit One
Goodwill [Line Items]
Purchase price, gross							$ 615,000,000	$ 45,000,000
Goodwill acquired during period	23,122,000	226,000	20,006,000			20,000,000
Goodwill, post-closing inventory and apportionment adjustment					200,000			2,800,000
Brand divested, sale price											22,300,000
Reduction in goodwill		6,382,000								6,400,000
Goodwill	190,911,000	167,546,000	173,702,000	154,896,000		20,232,000	17,401,000	2,831,000	23,122,000
Excess of fair value over carrying value, percentage	53.10%
Number of reporting units with fair value greater than carrying value	1
Intangible assets, net (including goodwill)	$ 1,585,728,000											$ 800,000

Intangible Assets (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended	12 Months Ended
	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, ending		$ 1,273,878
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, additions		10,256	11,678	9,988
Finite-lived intangibles, accumulated amortization, Effects of foreign currency exchange rates		1
Intangible Assets, Gross [Abstract]
Intangible assets, gross, beginning		1,446,942	1,463,084	838,935
Intangible assets, additions, gross	624,100	31,502	0	624,149
Intangible assets, reductions or disposals, gross		(158)	(16,142)	0
Intangible assets, Effects of foreign currency exchange rates		332
Intangible assets, gross, ending	1,446,942	1,478,618	1,446,942	1,463,084
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, beginning		73,702	62,562	52,574
Intangible assets, accumulated amortization, additions		10,256	11,678	9,988
Intangible assets, accumulated amortization, reductions or disposals		(158)	(538)	0
Intangible assets, accumulated amortization, ending	73,702	83,801	73,702	62,562
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net		120,939
Intangible Assets, Net [Abstract]
Intangible assets, net (excluding goodwill)	1,373,240	1,394,817	1,373,240	1,400,522
Finite Lived Trademarks
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived intangibles, gross, beginning		203,066	217,512	150,293
Finite-lived intangibles, additions, gross		1,657	1,696	67,219
Finite-lived intangibles, reductions or disposals, gross		0	(16,142)	0
Finite-lived intangibles,Effects of foreign currency exchange rates		17
Finite-lived intangibles, gross, ending	203,066	204,740	203,066	217,512
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-lived intangibles, accumulated amortization, beginning		73,544	62,404	52,416
Intangible assets, accumulated amortization, additions		10,256	11,678	9,988
Finite-lived intangibles, accumulated amortization, reductions or disposals		0	(538)	0
Finite-lived intangibles, accumulated amortization, Effects of foreign currency exchange rates		1
Finite-lived intangibles, accumulated amortization, ending	73,544	83,801	73,544	62,404
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, additions		10,256	11,678	9,988
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	129,522	120,939	129,522	155,108
Noncompete Agreements
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived intangibles, gross, beginning		158	158	158
Finite-lived intangibles, additions, gross		0	0	0
Finite-lived intangibles, reductions or disposals, gross		(158)	0	0
Finite-lived intangibles,Effects of foreign currency exchange rates		0
Finite-lived intangibles, gross, ending	158	0	158	158
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-lived intangibles, accumulated amortization, beginning		158	158	158
Intangible assets, accumulated amortization, additions		0	0	0
Finite-lived intangibles, accumulated amortization, reductions or disposals		(158)	0	0
Finite-lived intangibles, accumulated amortization, Effects of foreign currency exchange rates		0
Finite-lived intangibles, accumulated amortization, ending	158	0	158	158
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, additions		0	0	0
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	0	0	0	0
Indefinite Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning		1,243,718	1,245,414	688,484
Indefinite-lived intangibles, additions		29,845	(1,696)	556,930
Indefinite-lived intangibles, reductions or disposals		0	0	0
Indefinite-lived intangibles, Effects of foreign currency exchange rates		315
Indefinite-lived intangibles, ending	$ 1,243,718	$ 1,273,878	$ 1,243,718	$ 1,245,414

Intangible Assets (Narrative) (Details) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended			0 Months Ended		12 Months Ended		12 Months Ended
Intangible Assets (Narrative) (Details) (USD $)	Oct. 31, 2012	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Jan. 31, 2012 GSK Brands I	Mar. 30, 2012 GSK Brands II	Mar. 31, 2013 Care Pharma	Oct. 31, 2012 Phazyme	Mar. 31, 2014 Finite Lived Trademarks	Mar. 31, 2013 Finite Lived Trademarks	Mar. 31, 2012 Finite Lived Trademarks
Schedule of Intangible Assets [Line Items]
Purchase price, gross						$ 615,000,000	$ 45,000,000
Intangible assets acquired during period		624,100,000	31,502,000	0	624,149,000			31,500,000
Brand divested, sale price									22,300,000
Intangible assets, reductions, net	15,600,000
Finite-lived intangibles, additions, gross										$ 1,657,000	$ 1,696,000	$ 67,219,000

Intangible Assets (Expected Amortization Expense) (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, weighted average remaining period	13 years 6 months 0 days
Amortization of intangible assets	$ 10,256	$ 11,678	$ 9,988
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2015	8,950
2016	8,950
2017	8,950
2018	8,950
2019	8,950
Thereafter	76,189
Intangible assets, net	$ 120,939
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	30 years

Other Accrued Liabilities (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Payables and Accruals [Abstract]
Accrued marketing costs	$ 11,812	$ 17,187
Accrued compensation costs	6,232	8,847
Accrued broker commissions	1,019	1,028
Income taxes payable	1,854	493
Accrued professional fees	2,002	1,846
Deferred rent	1,258	1,268
Accrued production costs	1,506	0
Accrued lease termination costs	0	729
Other accrued liabilities	763	0
Total other accrued liabilities	$ 26,446	$ 31,398

Long-Term Debt (Narrative 2010 Senior Notes) (Details) (USD $)	3 Months Ended								12 Months Ended					0 Months Ended				3 Months Ended	9 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Dec. 17, 2013	Jan. 31, 2012	Jan. 16, 2014 Senior Notes 2010 Senior Notes	Dec. 17, 2013 Senior Notes 2010 Senior Notes	Nov. 01, 2010 Senior Notes 2010 Senior Notes	Mar. 24, 2010 Senior Notes 2010 Senior Notes	Dec. 31, 2013 Senior Notes 2010 Senior Notes	Dec. 31, 2013 Senior Notes 2010 Senior Notes	Mar. 31, 2014 Senior Notes 2010 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount																	$ 150,000,000.0
Debt instrument, stated interest rate																	8.25%
Debt instrument, increase, additional borrowings																100,000,000.0
Debt instrument, unamortized discount	3,086,000				7,100,000				3,086,000	7,100,000							2,200,000
Debt instrument, unamortized premium																300,000
Proceeds from issuance of long-term debt																100,300,000	147,800,000
Debt instrument, effective interest rate																				8.50%
Percentage of subsidiary owned	100.00%								100.00%			100.00%	100.00%
Premium percentage															6.33%
Repayment of notes									250,000,000	0	0			48,300,000	201,700,000
Loss on extinguishment of debt, redeemed debt																		15,000,000
Loss on extinguishment of debt	3,274,000	15,012,000	0	0	1,443,000	0	0	0	18,286,000	1,443,000	5,409,000							18,300,000
Additional loss on extinguishment of debt														3,300,000
Tendered debt														48,300,000
Repayments of Senior debt premium									15,527,000	0	0								15,500,000
Write off of deferred debt issuance cost																			2,200,000
Write off of debt discount																			$ 600,000

Long-Term Debt (Narrative 2012 Senior Notes) (Details) (USD $)	Mar. 31, 2014	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Percentage of subsidiary owned	100.00%	100.00%	100.00%
Senior Notes \| 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount			$ 250,000,000.0
Debt instrument, stated interest rate			8.125%
Debt issuance costs capitalized			$ 12,600,000

Long-Term Debt (Narrative 2012 Term Loan and 2012 ABL Revolver) (Details) (USD $)	3 Months Ended								12 Months Ended						0 Months Ended		3 Months Ended		0 Months Ended	3 Months Ended					0 Months Ended								0 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Dec. 17, 2013	Jan. 31, 2012	Jan. 31, 2012 Term Loan and ABL Revolver 2012	Jan. 31, 2012 Term Loans 2012 Term Loan	Mar. 31, 2014 Term Loans 2012 Term Loan	Mar. 31, 2013 Term Loans Amended 2012 Term Loan	Feb. 21, 2013 Term Loans Amended 2012 Term Loan	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver	Jun. 30, 2013 Revolving Credit Facility 2012 ABL Revolver	Mar. 31, 2014 Revolving Credit Facility 2012 ABL Revolver	Sep. 30, 2012 Revolving Credit Facility 2012 ABL Revolver	Jun. 30, 2013 Revolving Credit Facility 2010 Revolving Credit Facility	Sep. 30, 2012 Revolving Credit Facility 2010 Revolving Credit Facility	Feb. 21, 2013 LIBOR Term Loans Amended 2012 Term Loan	Jan. 31, 2012 LIBOR Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Base Rate Term Loans 2012 Term Loan	Jan. 31, 2012 Base Rate Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Federal Funds Rate Base Rate Term Loans 2012 Term Loan	Jan. 31, 2012 Federal Funds Rate Base Rate Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 LIBOR Base Rate Term Loans 2012 Term Loan	Jan. 31, 2012 LIBOR Base Rate Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Minimum LIBOR Term Loans 2012 Term Loan	Jan. 31, 2012 Minimum LIBOR Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Minimum Base Rate Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Maximum LIBOR Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Maximum Base Rate Revolving Credit Facility 2012 ABL Revolver	Dec. 20, 2011 GSK Brands brand
Debt Instrument [Line Items]
Debt instrument, face amount															$ 660,000,000.0
Debt instrument, term															7 years				5 years
Line of credit facility, increase in borrowing capacity																							20,000,000.0	25,000,000.0
Line of credit facility, maximum borrowing capacity																			50,000,000.0	95,000,000.0		75,000,000.0
Debt Instrument, Interest Rate, Increase (Decrease)																				(0.25%)
Debt instrument, discount, percentage															1.50%
Proceeds from issuance of long-term debt															650,100,000
Debt issuance costs capitalized														20,600,000
Percentage of subsidiary owned	100.00%								100.00%			100.00%	100.00%
Debt instrument, basis spread on variable rate																									2.75%								1.00%
Quarterly payment, percent of original principal amount															0.25%
Debt instrument, reference rate floor																		1.00%
Loss on extinguishment of debt	$ 3,274,000	$ 15,012,000	$ 0	$ 0	$ 1,443,000	$ 0	$ 0	$ 0	$ 18,286,000	$ 1,443,000	$ 5,409,000						$ 1,400,000
Debt instrument, basis spread on variable rate, fixed component																											2.00%		0.50%	0.50%	1.00%	1.00%
Debt instrument, variable rate																										1.75%		0.75%
Debt instrument, conditional variable rate																																		2.00%	1.00%	2.25%	1.25%
Line of credit facility, commitment fee percentage																			0.50%
Line of credit facility, conditional commitment fee percentage																			0.375%
Line of credit facility, interest rate at period end																3.90%					2.00%
Number of brands acquired																																						17

Long-Term Debt (Narrative 2013 Senior Notes) (Details) (USD $)	Mar. 31, 2014	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Percentage of subsidiary owned	100.00%	100.00%	100.00%
Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount		$ 400,000,000.0
Debt instrument, stated interest rate		5.375%
Debt issuance costs capitalized		$ 7,200,000

Long-Term Debt (Narrative Redemptions and Restrictions) (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014 Senior Notes 2012 Senior Notes	Mar. 31, 2014 Senior Notes 2013 Senior Notes	Mar. 31, 2014 Term Loans 2012 Term Loan	Jan. 31, 2012 Prior to February 1, 2016 [Member] Senior Notes 2012 Senior Notes	Jan. 31, 2012 Prior to February 1, 2015 [Member] Senior Notes 2012 Senior Notes	Jan. 31, 2012 Upon Change in Control Senior Notes 2012 Senior Notes	Dec. 31, 2013 Prior to December 15, 2016 [Member] Senior Notes 2013 Senior Notes	Dec. 31, 2013 On Or After December 15, 2016 [Member] Senior Notes 2013 Senior Notes	Mar. 31, 2014 Revolving Credit Facility 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount						100.00%	108.125%	101.00%	100.00%	105.375%
Unamortized debt issuance expense	$ 23,200,000
Debt instrument, percentage of principal amount eligible for redemption							35.00%		35.00%
Debt instrument, unamortized discount	3,086,000	7,100,000
Debt instrument, unamortized debt issuance expense and discount			$ 10,100,000	$ 7,000,000	$ 7,900,000						$ 1,300,000

Long-Term Debt (Schedule of Long-term Debt) (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 24, 2010
Debt Instrument [Line Items]
Long-term debt, gross	$ 937,500,000	$ 978,000,000
Current portion of long-term debt	0	0
Long-term debt, gross, excluding current maturities	937,500,000	978,000,000
Less: unamortized discount	(3,086,000)	(7,100,000)
Long-term debt, net of unamortized discount	934,414,000	970,900,000
Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	400,000,000	0
Senior Notes \| 2012 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	250,000,000	250,000,000
Senior Notes \| 2010 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	0	250,000,000
Less: unamortized discount			(2,200,000)
Term Loans \| 2012 Term Loan
Debt Instrument [Line Items]
Long-term debt, gross	287,500,000	445,000,000
Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Long-term debt, gross	$ 0	$ 33,000,000

Long-Term Debt (Maturities of Long-term Debt) (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Debt Disclosure [Abstract]
2015	$ 0
2016	0
2017	0
2018	0
2019	287,500,000
Thereafter	650,000,000
Long-term debt, gross	$ 937,500,000	$ 978,000,000

Fair Value Measurements (Details) (USD $) In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Senior Notes \| 2013 Senior Notes \| Carrying (Reported) Amount, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	$ 400.0
Senior Notes \| 2012 Senior Notes \| Carrying (Reported) Amount, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	250.0
Senior Notes \| 2010 Senior Notes \| Carrying (Reported) Amount, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure		250.0
Senior Notes \| Fair Value, Measurements, Nonrecurring \| Fair Value, Inputs, Level 2 \| 2013 Senior Notes \| Portion at Fair Value, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	408.5
Senior Notes \| Fair Value, Measurements, Nonrecurring \| Fair Value, Inputs, Level 2 \| 2012 Senior Notes \| Portion at Fair Value, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	280.6	281.9
Senior Notes \| Fair Value, Measurements, Nonrecurring \| Fair Value, Inputs, Level 2 \| 2010 Senior Notes \| Portion at Fair Value, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure		271.9
Term Loans \| 2012 Term Loan \| Carrying (Reported) Amount, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	287.5	445.0
Term Loans \| Fair Value, Measurements, Nonrecurring \| Fair Value, Inputs, Level 2 \| 2012 Term Loan \| Portion at Fair Value, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	288.9	451.1
Revolving Credit Facility \| 2012 ABL Revolver \| Carrying (Reported) Amount, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure		$ 33.0

Stockholders' Equity (Details) (USD $)	12 Months Ended
Stockholders' Equity (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Class of Stock [Line Items]
Common stock, shares authorized	250,000,000	250,000,000
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Voting rights, number of votes per common share owned	1
Dividends declared on common stock	$ 0
Dividends paid on common stock	$ 0
Restricted Shares
Class of Stock [Line Items]
Restricted stock repurchased during period, shares	25,464
Restricted stock acquired, average cost per share	$ 29.23

Earnings Per Share (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended								12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Numerator
Net income	$ 16,001	$ 3,130	$ 32,792	$ 20,692	$ 19,349	$ 12,257	$ 19,244	$ 14,655	$ 72,615	$ 65,505	$ 37,212
Denominator
Denominator for basic earnings per share- weighted average shares (in shares)	51,893	51,806	51,463	51,222	51,147	50,686	50,364	50,342	51,641	50,633	50,270
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors (in shares)									708	807	478
Denominator for diluted earnings per share (in shares)	52,513	52,445	52,219	52,040	51,913	51,523	51,225	51,106	52,349	51,440	50,748
Earnings per Common Share:
Basic net earnings per share (in USD per share)	$ 0.31	$ 0.06	$ 0.64	$ 0.40	$ 0.38	$ 0.24	$ 0.38	$ 0.29	$ 1.41	$ 1.29	$ 0.74
Diluted net earnings per share (in USD per share)	$ 0.30	$ 0.06	$ 0.63	$ 0.40	$ 0.37	$ 0.24	$ 0.38	$ 0.29	$ 1.39	$ 1.27	$ 0.73

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Earnings Per Share Antidilutive Securities (Details) (Outstanding Stock Awards) In Millions, unless otherwise specified	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	0.2	0	0.4

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

Share-Based Compensation (Narrative) (Details) (USD $)	0 Months Ended		12 Months Ended								0 Months Ended	12 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended			12 Months Ended	0 Months Ended			3 Months Ended	12 Months Ended	0 Months Ended
Share-Based Compensation (Narrative) (Details) (USD $)	Aug. 06, 2012	May 09, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2014 Restricted Shares	Mar. 31, 2013 Restricted Shares	Mar. 31, 2012 Restricted Shares	Mar. 31, 2014 Restricted Shares Minimum	Mar. 31, 2014 Restricted Shares Maximum	Aug. 06, 2012 Stock Options	Mar. 31, 2014 Stock Options Minimum	Aug. 06, 2012 Stock Options Maximum	Mar. 31, 2014 Stock Options Maximum	Nov. 05, 2013 Employee Restricted Stock Units (RSUs)	May 14, 2013 Employee Restricted Stock Units (RSUs)	May 09, 2012 Employee Restricted Stock Units (RSUs)	Mar. 31, 2014 Employee Restricted Stock Units (RSUs)	May 14, 2013 Employee Stock Options	Jan. 25, 2012 Management Restricted Stock Units (RSUs)	Jun. 29, 2012 Director Restricted Stock Units (RSUs)	Jun. 30, 2013 Director Restricted Stock Units (RSUs)	Mar. 31, 2014 Director Restricted Stock Units (RSUs)	Aug. 06, 2012 CEO Restricted Stock Units (RSUs)	Aug. 06, 2012 Common Stock Stock Options	May 14, 2013 Group One Employee Restricted Stock Units (RSUs)	May 14, 2013 Group Two Employee Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan			5,000,000.0
Share-based compensation costs charged against income			$ 5,146,000	$ 3,772,000	$ 3,078,000
Tax benefit recognized from share-based compensation expense			1,500,000	1,200,000	1,200,000
Restricted Shares
Award vesting period			10 months 13 days						3 years	5 years	3 years	3 years		5 years			3 years	3 years	3 years	3 years			1 year			3 years	3 years
Restricted common stock units granted in period, shares						126,600	128,900	217,500							6,000	113,637	111,152			95,000	12,652	7,004		5,109		55,637	58,000
Percentage of options vesting annually	33.30%																33.30%		33.30%								33.30%
Granted, weighted-average grant-date fair value (in USD per share)			$ 30.19	$ 13.59	$ 11.81	$ 30.19	$ 13.59	$ 11.81
Options
Award exercisability period, from date of grant													10 years	10 years					10 years
Options granted, shares		422,962	227,700	444,900	308,200
Options granted, weighted-average exercise price (in USD per share)		$ 13.24	$ 29.94	$ 13.36	$ 11.27
Common shares to be issued upon exercise																									21,978
Options granted, weighted-average grant-date fair value (in USD per share)	$ 15.66		$ 13.94	$ 6.03	$ 5.83														$ 29.94
Options granted in period																			227,672
Intrinsic value			14,000,000
Unrecognized compensation costs related to nonvested awards			3,700,000
Total fair value of vested shares			3,400,000	2,500,000	2,900,000
Cash received from exercise of stock options			5,900,000	6,000,000	600,000
Shares available for issuance under the Plan			1,600,000
Tax benefit realized from exercise of stock options			$ 1,700,000	$ 11,300,000	$ 300,000

Share-Based Compensation (Restricted Shares Activity) (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Weighted-Average Grant-Date Fair Value
Granted, weighted-average grant-date fair value (in USD per share)	$ 30.19	$ 13.59	$ 11.81
Restricted Shares
Shares
Outstanding, beginning of period	421,300	363,400	275,400
Granted	126,600	128,900	217,500
Vested and issued	(104,800)	(58,700)	(103,400)
Forfeited	(5,600)	(12,300)	(26,100)
Outstanding, end of period	437,500	421,300	363,400
Vested, end of period	69,600	70,400	54,000
Weighted-Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)	$ 11.01	$ 9.92	$ 8.46
Granted, weighted-average grant-date fair value (in USD per share)	$ 30.19	$ 13.59	$ 11.81
Vested, weighted-average grant-date fair value (in USD per share)	$ 9.98	$ 9.99	$ 9.93
Forfeited, weighted-average grant-date fair value (in USD per share)	$ 15.11	$ 10.69	$ 10.17
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)	$ 16.76	$ 11.01	$ 9.92
Vested, end of period, weighted-average grant-date fair value (in USD per share)	$ 9.34	$ 8.52	$ 7.40

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) (Stock Options, USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	48.00%	44.00%
Expected dividends	$ 0	$ 0
Expected term in years	6 years 0 months	6 years 6 months
Risk-free rate	1.30%	1.20%

Share-Based Compensation (Stock Option Activity) (Details) (USD $) In Thousands, except Share data, unless otherwise specified	0 Months Ended	12 Months Ended
	May 09, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Shares
Outstanding, beginning of period		1,386,400	1,745,400	1,621,500
Granted	422,962	227,700	444,900	308,200
Exercised		(605,000)	(786,500)	(86,900)
Forfeited or expired		(14,200)	(17,400)	(97,400)
Outstanding, end of period		994,900	1,386,400	1,745,400
Exercisable, end of period		173,600
Weighted-Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)		$ 10.43	$ 8.44	$ 8.19
Granted, weighted-average exercise price (in USD per share)	$ 13.24	$ 29.94	$ 13.36	$ 11.27
Exercised, weighted-average exercise price (in USD per share)		$ 9.76	$ 7.67	$ 10.24
Forfeited or expired, weighted-average exercise price (in USD per share)		$ 14.56	$ 11.21	$ 11.57
Outstanding, end of period, weighted-average exercise price (in USD per share)		$ 15.24	$ 10.43	$ 8.44
Exercisable, end of period, weighted-average exercise price (in USD per share)		$ 11.56
Options
Outstanding, end of period, weighted-average remaining contractual term		7 years 4 months 9 days
Exercisable, end of period, weighted-average remaining contractual term		6 years 9 months 20 days
Outstanding, end of period, aggregate intrinsic value		$ 7,387
Exercisable, end of period, aggregate intrinsic value		$ 1,181

Accumulated Other Comprehensive Income (Loss) (Components of AOCI) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Accumulated Other Comprehensive Income [Abstract]
Cumulative translation adjustment	$ 739	$ (104)
Accumulated other comprehensive income (loss), net of tax	$ 739	$ (104)

- Definition

Accumulated change, net of tax, in accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Includes an entity's share of an equity investee's Increase or Decrease in deferred hedging gains or losses.

+ References+ Details

- Definition

Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.

+ References+ Details

Income Taxes (Narrative) (Details) (USD $) In Millions, unless otherwise specified	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Ownership percentage	100.00%
Net operating loss carryforwards	$ 0.9
Operating loss carryforwards, limitation on use, annual amount	0.2
Earnings U.S income taxes not provided by	4.7
Uncertain tax liability	$ 0.4

- Definition

Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.

+ References+ Details

Income Taxes (Components of Provision for Income Taxes) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Current
Federal									$ 7,801	$ 12,520	$ 8,127
State									625	1,972	1,396
Foreign									1,675	532	630
Deferred
Federal									27,045	23,845	13,100
State									(7,879)	1,660	692
Foreign									(134)	0	0
Total provision for income taxes	$ 10,702	$ 1,056	$ 4,531	$ 12,844	$ 11,143	$ 7,804	$ 12,252	$ 9,330	$ 29,133	$ 40,529	$ 23,945

- Definition

Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

- Definition

Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

- Definition

Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

- Definition

Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

- Definition

Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

Income Taxes (Components of Deferred Tax Balances) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$ 4,082	$ 2,807
Inventory capitalization	1,301	1,370
Inventory reserves	362	525
Net operating loss carryforwards	327	411
State income taxes	3,728	7,364
Accrued liabilities	642	1,896
Stock compensation	2,358	2,367
Other	702	496
Total deferred tax assets	13,502	17,236
Deferred Tax Liabilities
Property and equipment	(1,467)	(1,504)
Intangible assets	(218,696)	(203,671)
Total deferred tax liabilities	(220,163)	(205,175)
Net deferred tax liability	$ (206,661)	$ (187,939)

Income Taxes (Reconciliation of Effective Tax Rate) (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Income Tax Disclosure [Abstract]
Income tax provision at statutory rate	$ 35,612	$ 37,112	$ 21,405
Income tax provision at statutory rate, percentage	35.00%	35.00%	35.00%
Foreign tax (benefit) provision	(918)	0	191
Foreign tax (benefit) provision, percentage	(0.90%)	0.00%	0.30%
State income taxes, net of federal income tax benefit	2,004	3,413	2,073
State income taxes, net of federal income tax benefit, percentage	2.00%	3.20%	3.40%
Decrease in net deferred tax liability resulting from a change in the effective state tax rate	(8,892)	(1,741)	(1,177)
Decrease in net deferred tax liability resulting from a change in the effective state tax rate, percentage	(8.70%)	(1.60%)	(1.90%)
Nondeductible compensation	1,011	1,684	1,305
Nondeductible compensation, percentage	1.00%	1.60%	2.10%
Other	316	61	148
Other, percentage	0.30%	0.00%	0.30%
Total provision for income taxes	$ 29,133	$ 40,529	$ 23,945
Total provision for income taxes, percentage	28.70%	38.20%	39.20%

Income Taxes (Uncertain Tax Liability Activity) (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance – beginning of year	$ 1,016	$ 292
Additions based on tax positions related to the current year	360	831
Reductions based on lapse of statute of limitations	(140)	(107)
Balance – end of year	$ 1,236	$ 1,016

Commitments and Contingencies (Future Minimum Rental Payments) (Details) (USD $)	12 Months Ended				3 Months Ended	1 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2014 Office Facilities	Dec. 31, 2012 New York	May 31, 2012 Arkansas	Mar. 31, 2014 Equipment
Operating Leased Assets [Line Items]
Operating lease, term					5 years 6 months	3 years
2015	$ 1,357,000			$ 1,221,000			$ 136,000
2016	1,129,000			994,000			135,000
2017	1,091,000			1,023,000			68,000
2018	1,044,000			1,044,000			0
2019	0			0			0
Total future minimum payments due	4,621,000			4,282,000			339,000
Operating leases, rent expense	$ 1,500,000	$ 1,200,000	$ 900,000

Commitments and Contingencies (Long-term Supply Agreement) (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014
Long-term Purchase Commitment [Line Items]
2015	$ 1,105
2016	1,074
2017	1,044
2018	1,013
2019	982
Thereafter	560
Total purchase commitment	$ 5,778
Third-party Manufacturing
Long-term Purchase Commitment [Line Items]
Supply agreement, term	10 years

Concentrations of Risk (Details)	12 Months Ended
Concentrations of Risk (Details)	Mar. 31, 2014 brand	Mar. 31, 2013	Mar. 31, 2012
Concentration Risk [Line Items]
Number of third-party manufacturers	50
Sales \| Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	38.30%	40.50%	51.30%
Number of highest selling brands comprising group against which concentration risk is measured	5
Sales \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	19.50%	15.90%	18.90%
Number of customers exceeding concentration risk benchmark	1	1	1
Sales \| Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	82.40%	75.30%
Number of third-party manufacturers with long-term contracts	24	22
Accounts Receivable \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	24.10%

Business Segments (Information on Operating and Reportable Segments) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2014 OTC Healthcare	Mar. 31, 2013 OTC Healthcare	Mar. 31, 2012 OTC Healthcare	Mar. 31, 2014 Household Cleaning	Mar. 31, 2013 Household Cleaning	Mar. 31, 2012 Household Cleaning	Mar. 31, 2014 Geographic Concentration Risk Sales United States	Mar. 31, 2013 Geographic Concentration Risk Sales United States	Mar. 31, 2010 Geographic Concentration Risk Sales United States	Mar. 31, 2014 Geographic Concentration Risk Sales Canada	Mar. 31, 2013 Geographic Concentration Risk Sales Canada	Mar. 31, 2010 Geographic Concentration Risk Sales Canada
Segment Reporting Information, Profit (Loss):
Net sales									$ 596,954	$ 620,394	$ 437,838	$ 513,056	$ 536,247	$ 344,282	$ 83,898	$ 84,147	$ 93,556
Other revenues									4,927	3,203	3,247	791	684	719	4,136	2,519	2,528
Total revenues	144,256	146,212	168,442	142,971	154,513	160,232	161,855	146,997	601,881	623,597	441,085	513,847	536,931	345,001	88,034	86,666	96,084
Cost of sales (exclusive of depreciation shown below)	64,216	64,403	73,723	59,488	66,443	75,235	71,310	63,393	261,830	276,381	213,701	197,442	211,654	143,151	64,388	64,727	70,550
Gross profit	80,040	81,809	94,719	83,483	88,070	84,997	90,545	83,604	340,051	347,216	227,384	316,405	325,277	201,850	23,646	21,939	25,534
Advertising and promotion	18,714	25,570	26,044	19,140	23,259	23,538	23,508	20,325	89,468	90,630	57,127	86,578	84,537	51,895	2,890	6,093	5,232
Contribution margin									250,583	256,586	170,257	229,827	240,740	149,955	20,756	15,846	20,302
Other operating expenses									61,967	64,702	67,434
Operating income	44,955	40,458	53,762	49,441	50,173	46,722	51,156	43,833	188,616	191,884	102,823
Other expense									86,868	85,850	41,666
Income before income taxes	26,703	4,186	37,323	33,536	30,492	20,061	31,496	23,985	101,748	106,034	61,157
Provision for income taxes	10,702	1,056	4,531	12,844	11,143	7,804	12,252	9,330	29,133	40,529	23,945
Net income	$ 16,001	$ 3,130	$ 32,792	$ 20,692	$ 19,349	$ 12,257	$ 19,244	$ 14,655	$ 72,615	$ 65,505	$ 37,212
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage																		86.90%	89.90%	90.20%	7.70%	7.40%	6.30%

Business Segments (Revenue by Product) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Revenue from External Customer [Line Items]
Revenues	$ 144,256	$ 146,212	$ 168,442	$ 142,971	$ 154,513	$ 160,232	$ 161,855	$ 146,997	$ 601,881	$ 623,597	$ 441,085
OTC Healthcare
Revenue from External Customer [Line Items]
Revenues									513,847	536,931	345,001
OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Revenues									110,604	108,144	18,930
OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Revenues									115,241	126,974	116,669
OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Revenues									83,971	97,940	29,489
OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues									86,390	86,380	74,363
OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Revenues									52,363	52,401	52,592
OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Revenues									48,774	49,617	46,551
OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Revenues									16,504	15,475	6,407
Household Cleaning
Revenue from External Customer [Line Items]
Revenues									$ 88,034	$ 86,666	$ 96,084

Business Segments (Assets by Segment) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2011
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 190,911	$ 167,546	$ 173,702	$ 154,896
Indefinite-lived intangibles	1,273,878
Finite-lived intangibles	120,939
Intangible assets, net (excluding goodwill)	1,394,817	1,373,240	1,400,522
Intangible assets, net (including goodwill)	1,585,728
OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	183,522	160,157	166,313	147,507
Indefinite-lived intangibles	1,154,058
Finite-lived intangibles	94,772
Intangible assets, net (excluding goodwill)	1,248,830
Intangible assets, net (including goodwill)	1,432,352
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	7,389	7,389	7,389	7,389
Indefinite-lived intangibles	119,820
Finite-lived intangibles	26,167
Intangible assets, net (excluding goodwill)	145,987
Intangible assets, net (including goodwill)	$ 153,376

Gain on Settlement (Details) (USD $)	0 Months Ended	12 Months Ended
Gain on Settlement (Details) (USD $)	Jun. 15, 2011	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Loss Contingencies [Line Items]
Proceeds from settlement of pending litigation	$ 8,000,000
Litigation settlement, costs incurred				2,900,000
Gain on settlement		0	0	5,063,000
Gain on settlement, net of tax				3,200,000
Individual Counterparty
Loss Contingencies [Line Items]
Number of defendants	2
Other (Income) Expense
Loss Contingencies [Line Items]
Gain on settlement				$ 5,100,000

Unaudited Quarterly Financial Information (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended								12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 144,256	$ 146,212	$ 168,442	$ 142,971	$ 154,513	$ 160,232	$ 161,855	$ 146,997	$ 601,881	$ 623,597	$ 441,085
Cost of sales (exclusive of depreciation shown below)	64,216	64,403	73,723	59,488	66,443	75,235	71,310	63,393	261,830	276,381	213,701
Gross profit	80,040	81,809	94,719	83,483	88,070	84,997	90,545	83,604	340,051	347,216	227,384
Operating Expenses
Advertising and promotion	18,714	25,570	26,044	19,140	23,259	23,538	23,508	20,325	89,468	90,630	57,127
General and administrative	13,091	12,137	11,619	11,634	11,353	11,378	12,585	16,151	48,481	51,467	56,700
Depreciation and amortization	3,280	3,644	3,294	3,268	3,285	3,359	3,296	3,295	13,486	13,235	10,734
Total operating expenses	35,085	41,351	40,957	34,042	37,897	38,275	39,389	39,771	151,435	155,332	124,561
Operating income	44,955	40,458	53,762	49,441	50,173	46,722	51,156	43,833	188,616	191,884	102,823
Net interest expense	14,978	21,260	16,439	15,905	18,238	26,661	19,660	19,848
Loss on extinguishment of debt	3,274	15,012	0	0	1,443	0	0	0	18,286	1,443	5,409
Income before income taxes	26,703	4,186	37,323	33,536	30,492	20,061	31,496	23,985	101,748	106,034	61,157
Provision for income taxes	10,702	1,056	4,531	12,844	11,143	7,804	12,252	9,330	29,133	40,529	23,945
Net income	16,001	3,130	32,792	20,692	19,349	12,257	19,244	14,655	72,615	65,505	37,212
Earnings per share:
Basic (in USD per share)	$ 0.31	$ 0.06	$ 0.64	$ 0.40	$ 0.38	$ 0.24	$ 0.38	$ 0.29	$ 1.41	$ 1.29	$ 0.74
Diluted (in USD per share)	$ 0.30	$ 0.06	$ 0.63	$ 0.40	$ 0.37	$ 0.24	$ 0.38	$ 0.29	$ 1.39	$ 1.27	$ 0.73
Weighted average shares outstanding:
Basic (in shares)	51,893	51,806	51,463	51,222	51,147	50,686	50,364	50,342	51,641	50,633	50,270
Diluted (in shares)	52,513	52,445	52,219	52,040	51,913	51,523	51,225	51,106	52,349	51,440	50,748
Comprehensive income, net of tax:
Currency translation adjustments	2,414	(2,694)	1,122	1	(114)	(1)	66	(42)	843	(91)	(13)
Total other comprehensive income (loss)	2,414	(2,694)	1,122	1	(114)	(1)	66	(42)	843	(91)	(13)
Comprehensive income	$ 18,415	$ 436	$ 33,914	$ 20,693	$ 19,235	$ 12,256	$ 19,310	$ 14,613	$ 73,458	$ 65,414	$ 37,199

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Revenues
Net sales									$ 596,954	$ 620,394	$ 437,838
Other revenues									4,927	3,203	3,247
Total revenues	144,256	146,212	168,442	142,971	154,513	160,232	161,855	146,997	601,881	623,597	441,085
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	64,216	64,403	73,723	59,488	66,443	75,235	71,310	63,393	261,830	276,381	213,701
Gross profit	80,040	81,809	94,719	83,483	88,070	84,997	90,545	83,604	340,051	347,216	227,384
Operating Expenses
Advertising and promotion	18,714	25,570	26,044	19,140	23,259	23,538	23,508	20,325	89,468	90,630	57,127
General and administrative	13,091	12,137	11,619	11,634	11,353	11,378	12,585	16,151	48,481	51,467	56,700
Depreciation and amortization	3,280	3,644	3,294	3,268	3,285	3,359	3,296	3,295	13,486	13,235	10,734
Total operating expenses	35,085	41,351	40,957	34,042	37,897	38,275	39,389	39,771	151,435	155,332	124,561
Operating income	44,955	40,458	53,762	49,441	50,173	46,722	51,156	43,833	188,616	191,884	102,823
Other (income) expense
Interest income									(60)	(13)	(18)
Interest expense									68,642	84,420	41,338
Gain on settlement									0	0	(5,063)
Loss on extinguishment of debt	3,274	15,012	0	0	1,443	0	0	0	18,286	1,443	5,409
Equity in income of subsidiaries									0	0	0
Total other expense									86,868	85,850	41,666
Income before income taxes	26,703	4,186	37,323	33,536	30,492	20,061	31,496	23,985	101,748	106,034	61,157
Provision (benefit) for income taxes	10,702	1,056	4,531	12,844	11,143	7,804	12,252	9,330	29,133	40,529	23,945
Net income (loss)	16,001	3,130	32,792	20,692	19,349	12,257	19,244	14,655	72,615	65,505	37,212
Comprehensive income, net of tax:
Currency translation adjustments									843	(91)	(13)
Total other comprehensive income (loss)	2,414	(2,694)	1,122	1	(114)	(1)	66	(42)	843	(91)	(13)
Comprehensive income	18,415	436	33,914	20,693	19,235	12,256	19,310	14,613	73,458	65,414	37,199
Prestige Brands Holdings, Inc.
Revenues
Net sales									0	0	0
Other revenues									0	0	0
Total revenues									0	0	0
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									0	0	0
Gross profit									0	0	0
Operating Expenses
Advertising and promotion									0	0	0
General and administrative									3,140	5,127	17,181
Depreciation and amortization									2,994	1,346	538
Total operating expenses									6,134	6,473	17,719
Operating income									(6,134)	(6,473)	(17,719)
Other (income) expense
Interest income									(48,730)	(30,561)	(50,357)
Interest expense									34,436	34,671	35,004
Gain on settlement											(5,063)
Loss on extinguishment of debt									0	0	0
Equity in income of subsidiaries									(66,739)	(72,295)	(35,571)
Total other expense									(81,033)	(68,185)	(55,987)
Income before income taxes									74,899	61,712	38,268
Provision (benefit) for income taxes									2,284	(3,793)	1,056
Net income (loss)									72,615	65,505	37,212
Comprehensive income, net of tax:
Currency translation adjustments									843	(91)	(13)
Total other comprehensive income (loss)									843	(91)	(13)
Comprehensive income									73,458	65,414	37,199
Prestige Brands, Inc., the issuer
Revenues
Net sales									98,278	102,706	100,542
Other revenues									295	278	229
Total revenues									98,573	102,984	100,771
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									37,272	39,333	36,658
Gross profit									61,301	63,651	64,113
Operating Expenses
Advertising and promotion									10,992	12,605	11,918
General and administrative									8,026	6,917	10,059
Depreciation and amortization									577	569	570
Total operating expenses									19,595	20,091	22,547
Operating income									41,706	43,560	41,566
Other (income) expense
Interest income									(57,446)	(57,496)	(44,269)
Interest expense									68,642	84,420	76,341
Gain on settlement											0
Loss on extinguishment of debt									18,286	1,443	5,409
Equity in income of subsidiaries									(53,836)	(65,784)	(37,192)
Total other expense									(24,354)	(37,417)	289
Income before income taxes									66,060	80,977	41,277
Provision (benefit) for income taxes									3,500	5,807	1,599
Net income (loss)									62,560	75,170	39,678
Comprehensive income, net of tax:
Currency translation adjustments									843	0	0
Total other comprehensive income (loss)									843	0	0
Comprehensive income									63,403	75,170	39,678
Combined Subsidiary Guarantors
Revenues
Net sales									478,069	513,017	333,407
Other revenues									4,886	3,158	3,212
Total revenues									482,955	516,175	336,619
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									218,692	236,795	177,112
Gross profit									264,263	279,380	159,507
Operating Expenses
Advertising and promotion									73,314	76,599	43,906
General and administrative									34,469	38,713	28,698
Depreciation and amortization									9,715	11,261	9,556
Total operating expenses									117,498	126,573	82,160
Operating income									146,765	152,807	77,347
Other (income) expense
Interest income									(2,327)	0	0
Interest expense									72,064	53,374	24,822
Gain on settlement											0
Loss on extinguishment of debt									0	0	0
Equity in income of subsidiaries									(4,052)	(1,482)	(1,313)
Total other expense									65,685	51,892	23,509
Income before income taxes									81,080	100,915	53,838
Provision (benefit) for income taxes									22,055	38,006	20,565
Net income (loss)									59,025	62,909	33,273
Comprehensive income, net of tax:
Currency translation adjustments									843	0	0
Total other comprehensive income (loss)									843	0	0
Comprehensive income									59,868	62,909	33,273
Combined Non-guarantor Subsidiaries
Revenues
Net sales									23,286	4,671	3,889
Other revenues									1,639	1,517	1,475
Total revenues									24,925	6,188	5,364
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									9,428	2,003	1,600
Gross profit									15,497	4,185	3,764
Operating Expenses
Advertising and promotion									5,162	1,426	1,303
General and administrative									2,846	710	762
Depreciation and amortization									200	59	70
Total operating expenses									8,208	2,195	2,135
Operating income									7,289	1,990	1,629
Other (income) expense
Interest income									(382)	(1)	(221)
Interest expense									2,325	0	0
Gain on settlement											0
Loss on extinguishment of debt									0	0	0
Equity in income of subsidiaries									0	0	0
Total other expense									1,943	(1)	(221)
Income before income taxes									5,346	1,991	1,850
Provision (benefit) for income taxes									1,294	509	725
Net income (loss)									4,052	1,482	1,125
Comprehensive income, net of tax:
Currency translation adjustments									843	(91)	13
Total other comprehensive income (loss)									843	(91)	13
Comprehensive income									4,895	1,391	1,138
Eliminations
Revenues
Net sales									(2,679)	0	0
Other revenues									(1,893)	(1,750)	(1,669)
Total revenues									(4,572)	(1,750)	(1,669)
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									(3,562)	(1,750)	(1,669)
Gross profit									(1,010)	0	0
Operating Expenses
Advertising and promotion									0	0	0
General and administrative									0	0	0
Depreciation and amortization									0	0	0
Total operating expenses									0	0	0
Operating income									(1,010)	0	0
Other (income) expense
Interest income									108,825	88,045	94,829
Interest expense									(108,825)	(88,045)	(94,829)
Gain on settlement											0
Loss on extinguishment of debt									0	0	0
Equity in income of subsidiaries									124,627	139,561	74,076
Total other expense									124,627	139,561	74,076
Income before income taxes									(125,637)	(139,561)	(74,076)
Provision (benefit) for income taxes									0	0	0
Net income (loss)									(125,637)	(139,561)	(74,076)
Comprehensive income, net of tax:
Currency translation adjustments									(2,529)	91	(13)
Total other comprehensive income (loss)									(2,529)	91	(13)
Comprehensive income									$ (128,166)	$ (139,470)	$ (74,089)

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2011
Condensed Financial Statements, Captions [Line Items]
Ownership percentage	100.00%
Current assets
Cash and cash equivalents	$ 28,331	$ 15,670	$ 19,015	$ 13,334
Accounts receivable, net	65,050	73,053
Inventories	65,586	60,201
Deferred income tax assets	6,544	6,349
Prepaid expenses and other current assets	11,674	8,900
Total current assets	177,185	164,173
Property and equipment, net	9,597	9,896
Goodwill	190,911	167,546	173,702	154,896
Intangible assets, net	1,394,817	1,373,240	1,400,522
Other long-term assets	23,153	24,944
Intercompany receivable	0	0
Investment in subsidiary	0	0
Total Assets	1,795,663	1,739,799
Current liabilities
Accounts payable	48,286	51,376
Accrued interest payable	9,626	13,894
Other accrued liabilities	26,446	31,398
Total current liabilities	84,358	96,668
Long-term debt
Principal amount	937,500	978,000
Less unamortized discount	(3,086)	(7,100)
Long-term debt, net of unamortized discount	934,414	970,900
Deferred income tax liabilities	213,204	194,288
Other long-term liabilities	327	0
Intercompany payable	0	0
Total Liabilities	1,232,303	1,261,856
Stockholders’ Equity
Preferred share rights	0	283
Common Stock	520	513
Additional paid-in capital	414,387	401,691
Treasury stock, at cost	(1,431)	(687)
Accumulated other comprehensive income (loss), net of tax	739	(104)
Retained earnings (accumulated deficit)	149,145	76,247
Total Stockholders’ Equity	563,360	477,943	402,728	361,832
Total Liabilities and Stockholders’ Equity	1,795,663	1,739,799
Prestige Brands Holdings, Inc.
Current assets
Cash and cash equivalents	24,644	14,720	18,221	12,698
Accounts receivable, net	473	21
Inventories	0	0
Deferred income tax assets	260	218
Prepaid expenses and other current assets	8,004	4,942
Total current assets	33,381	19,901
Property and equipment, net	8,966	9,609
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivable	655,146	653,049
Investment in subsidiary	1,497,357	1,429,775
Total Assets	2,194,850	2,112,334
Current liabilities
Accounts payable	4,416	2,601
Accrued interest payable	0	0
Other accrued liabilities	7,728	12,694
Total current liabilities	12,144	15,295
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0
Intercompany payable	1,619,346	1,619,096
Total Liabilities	1,631,490	1,634,391
Stockholders’ Equity
Preferred share rights		283
Common Stock	520	513
Additional paid-in capital	414,387	401,691
Treasury stock, at cost	(1,431)	(687)
Accumulated other comprehensive income (loss), net of tax	739	(104)
Retained earnings (accumulated deficit)	149,145	76,247
Total Stockholders’ Equity	563,360	477,943
Total Liabilities and Stockholders’ Equity	2,194,850	2,112,334
Prestige Brands, Inc., the issuer
Condensed Financial Statements, Captions [Line Items]
Ownership percentage	100.00%
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	14,245	13,875
Inventories	14,357	11,164
Deferred income tax assets	925	855
Prepaid expenses and other current assets	113	93
Total current assets	29,640	25,987
Property and equipment, net	112	34
Goodwill	66,007	66,007
Intangible assets, net	192,861	193,396
Other long-term assets	23,153	24,944
Intercompany receivable	1,824,482	1,911,573
Investment in subsidiary	749,947	638,611
Total Assets	2,886,202	2,860,552
Current liabilities
Accounts payable	7,658	10,600
Accrued interest payable	9,626	13,894
Other accrued liabilities	2,117	1,684
Total current liabilities	19,401	26,178
Long-term debt
Principal amount	937,500	978,000
Less unamortized discount	(3,086)	(7,100)
Long-term debt, net of unamortized discount	934,414	970,900
Deferred income tax liabilities	56,827	55,291
Other long-term liabilities	0
Intercompany payable	451,497	447,419
Total Liabilities	1,462,139	1,499,788
Stockholders’ Equity
Preferred share rights		0
Common Stock	0	0
Additional paid-in capital	1,280,945	1,280,945
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	739	0
Retained earnings (accumulated deficit)	142,379	79,819
Total Stockholders’ Equity	1,424,063	1,360,764
Total Liabilities and Stockholders’ Equity	2,886,202	2,860,552
Combined Subsidiary Guarantors
Condensed Financial Statements, Captions [Line Items]
Ownership percentage	100.00%
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	45,885	58,345
Inventories	46,309	48,474
Deferred income tax assets	4,914	5,276
Prepaid expenses and other current assets	2,898	3,609
Total current assets	100,006	115,704
Property and equipment, net	226	253
Goodwill	101,540	101,539
Intangible assets, net	1,169,943	1,179,524
Other long-term assets	0	0
Intercompany receivable	656,759	415,587
Investment in subsidiary	34,562	7,067
Total Assets	2,063,036	1,819,674
Current liabilities
Accounts payable	33,553	37,695
Accrued interest payable	0	0
Other accrued liabilities	13,443	16,107
Total current liabilities	46,996	53,802
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	156,327	138,924
Other long-term liabilities	0
Intercompany payable	1,037,105	920,865
Total Liabilities	1,240,428	1,113,591
Stockholders’ Equity
Preferred share rights		0
Common Stock	0	0
Additional paid-in capital	681,503	624,742
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	739	0
Retained earnings (accumulated deficit)	140,366	81,341
Total Stockholders’ Equity	822,608	706,083
Total Liabilities and Stockholders’ Equity	2,063,036	1,819,674
Combined Non-guarantor Subsidiaries
Current assets
Cash and cash equivalents	3,687	950	794	636
Accounts receivable, net	4,447	812
Inventories	5,930	563
Deferred income tax assets	445	0
Prepaid expenses and other current assets	659	256
Total current assets	15,168	2,581
Property and equipment, net	293	0
Goodwill	23,364	0
Intangible assets, net	32,013	320
Other long-term assets	0	0
Intercompany receivable	13,595	7,316
Investment in subsidiary	0	0
Total Assets	84,433	10,217
Current liabilities
Accounts payable	2,659	480
Accrued interest payable	0	0
Other accrued liabilities	3,158	913
Total current liabilities	5,817	1,393
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	50	73
Other long-term liabilities	327
Intercompany payable	42,034	145
Total Liabilities	48,228	1,611
Stockholders’ Equity
Preferred share rights		0
Common Stock	0	0
Additional paid-in capital	23,815	1,111
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	739	(104)
Retained earnings (accumulated deficit)	11,651	7,599
Total Stockholders’ Equity	36,205	8,606
Total Liabilities and Stockholders’ Equity	84,433	10,217
Eliminations
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0
Inventories	(1,010)	0
Deferred income tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	(1,010)	0
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivable	(3,149,982)	(2,987,525)
Investment in subsidiary	(2,281,866)	(2,075,453)
Total Assets	(5,432,858)	(5,062,978)
Current liabilities
Accounts payable	0	0
Accrued interest payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0
Intercompany payable	(3,149,982)	(2,987,525)
Total Liabilities	(3,149,982)	(2,987,525)
Stockholders’ Equity
Preferred share rights		0
Common Stock	0	0
Additional paid-in capital	(1,986,263)	(1,906,798)
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	(2,217)	104
Retained earnings (accumulated deficit)	(294,396)	(168,759)
Total Stockholders’ Equity	(2,282,876)	(2,075,453)
Total Liabilities and Stockholders’ Equity	$ (5,432,858)	$ (5,062,978)

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Operating Activities
Net income (loss)	$ 72,615	$ 65,505	$ 37,212
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	13,486	13,235	10,734
Deferred income taxes	19,012	25,505	13,793
Amortization of deferred financing costs	7,102	9,832	1,630
Stock-based compensation costs	5,146	3,772	3,078
Loss on extinguishment of debt	18,286	1,443	5,409
Premium payment on 2010 Senior Notes	(15,527)	0	0
Amortization of debt discount	3,410	4,632	1,030
Lease termination costs	0	975	0
Loss on disposal of equipment	(3)	103	0
Equity in income of subsidiaries	0	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	9,735	(12,882)	(15,854)
Inventories	(2,850)	(9,342)	3,710
Prepaid expenses and other current assets	(2,130)	3,096	(3,009)
Accounts payable	(4,641)	24,677	5,127
Accrued liabilities	(12,059)	7,054	4,592
Net cash provided by operating activities	111,582	137,605	67,452
Investing Activities
Purchases of property and equipment	(2,764)	(10,268)	(606)
Proceeds from the sale of property and equipment	3	15	0
Proceeds from escrow of Blacksmith acquisition	0	0	1,200
Proceeds from the sale of Phazyme brand	0	21,700	0
Acquisition of brands	(55,215)		(662,800)
Acquisition of brands from GSK purchase price adjustments	0	(226)	0
Intercompany activity, net	0	0	0
Net cash (used in) provided by investing activities	(57,976)	11,221	(662,206)
Financing Activities
Repayments of long-term debt	(157,500)	(190,000)	(25,000)
Repayments under revolving credit agreement	(83,000)	(15,000)	0
Proceeds from issuance of Senior Notes	400,000	0	250,000
Repayment of 2010 Term Loan	0	0	(242,000)
Repayment of 2010 Senior Notes	(250,000)	0	0
Borrowings under revolving credit agreement	50,000	48,000	0
Proceeds from issuance of 2012 Term Loan	0	0	650,100
Payment of deferred financing costs	(7,466)	(1,146)	(33,284)
Proceeds from exercise of stock options	5,907	6,029	889
Excess tax benefits from share-based awards	1,650	0	0
Fair value of shares surrendered as payment of tax withholding	(744)	0	(271)
Intercompany activity, net	0	0	0
Net cash (used in) provided by financing activities	(41,153)	(152,117)	600,434
Effects of exchange rate changes on cash and cash equivalents	208	(54)	1
Increase (decrease) in cash and cash equivalents	12,661	(3,345)	5,681
Cash and cash equivalents - beginning of year	15,670	19,015	13,334
Cash and cash equivalents - end of year	28,331	15,670	19,015
Prestige Brands Holdings, Inc.
Operating Activities
Net income (loss)	72,615	65,505	37,212
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	2,994	1,346	538
Deferred income taxes	(42)	138	290
Amortization of deferred financing costs	0	0	0
Stock-based compensation costs	5,146	3,772	3,078
Loss on extinguishment of debt	0	0	0
Premium payment on 2010 Senior Notes	0
Amortization of debt discount	0	0	0
Lease termination costs		975
Loss on disposal of equipment	0	82
Equity in income of subsidiaries	(66,739)	(72,295)	(35,571)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(452)	4	(12)
Inventories	0	0	0
Prepaid expenses and other current assets	(3,062)	3,160	(3,598)
Accounts payable	1,815	(1,930)	2,611
Accrued liabilities	(4,966)	(39)	417
Net cash provided by operating activities	7,309	718	4,965
Investing Activities
Purchases of property and equipment	(2,351)	(10,268)	(367)
Proceeds from the sale of property and equipment	0	0
Proceeds from escrow of Blacksmith acquisition			0
Proceeds from the sale of Phazyme brand		0
Acquisition of brands	0		0
Acquisition of brands from GSK purchase price adjustments		0
Intercompany activity, net	0	(226)	1,200
Net cash (used in) provided by investing activities	(2,351)	(10,494)	833
Financing Activities
Repayments of long-term debt	0	0	0
Repayments under revolving credit agreement	0	0
Proceeds from issuance of Senior Notes	0		0
Repayment of 2010 Term Loan			0
Repayment of 2010 Senior Notes	0
Borrowings under revolving credit agreement	0	0
Proceeds from issuance of 2012 Term Loan			0
Payment of deferred financing costs	0	0	0
Proceeds from exercise of stock options	5,907	6,029	889
Excess tax benefits from share-based awards	1,650
Fair value of shares surrendered as payment of tax withholding	(744)		(271)
Intercompany activity, net	(1,847)	246	(893)
Net cash (used in) provided by financing activities	4,966	6,275	(275)
Effects of exchange rate changes on cash and cash equivalents	0	0	0
Increase (decrease) in cash and cash equivalents	9,924	(3,501)	5,523
Cash and cash equivalents - beginning of year	14,720	18,221	12,698
Cash and cash equivalents - end of year	24,644	14,720	18,221
Prestige Brands, Inc., the issuer
Operating Activities
Net income (loss)	62,560	75,170	39,678
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	577	569	570
Deferred income taxes	1,466	4,341	3,514
Amortization of deferred financing costs	7,102	9,832	1,630
Stock-based compensation costs	0	0	0
Loss on extinguishment of debt	18,286	1,443	5,409
Premium payment on 2010 Senior Notes	(15,527)
Amortization of debt discount	3,410	4,632	1,030
Lease termination costs		0
Loss on disposal of equipment	0	0
Equity in income of subsidiaries	(53,836)	(65,784)	(37,192)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(370)	(373)	(3,412)
Inventories	(3,193)	(3,066)	1,459
Prepaid expenses and other current assets	(20)	(37)	(20)
Accounts payable	(2,942)	5,784	(1,598)
Accrued liabilities	(3,835)	2	2,984
Net cash provided by operating activities	13,678	32,513	14,052
Investing Activities
Purchases of property and equipment	(119)	0	0
Proceeds from the sale of property and equipment	0	0
Proceeds from escrow of Blacksmith acquisition			0
Proceeds from the sale of Phazyme brand		0
Acquisition of brands	0		0
Acquisition of brands from GSK purchase price adjustments		0
Intercompany activity, net	(55,215)	0	(662,800)
Net cash (used in) provided by investing activities	(55,334)	0	(662,800)
Financing Activities
Repayments of long-term debt	(157,500)	(190,000)	(25,000)
Repayments under revolving credit agreement	(83,000)	(15,000)
Proceeds from issuance of Senior Notes	400,000		250,000
Repayment of 2010 Term Loan			(242,000)
Repayment of 2010 Senior Notes	(250,000)
Borrowings under revolving credit agreement	50,000	48,000
Proceeds from issuance of 2012 Term Loan			650,100
Payment of deferred financing costs	(7,466)	(1,146)	(33,284)
Proceeds from exercise of stock options	0	0	0
Excess tax benefits from share-based awards	0
Fair value of shares surrendered as payment of tax withholding	0		0
Intercompany activity, net	89,622	125,633	48,932
Net cash (used in) provided by financing activities	41,656	(32,513)	648,748
Effects of exchange rate changes on cash and cash equivalents	0	0	0
Increase (decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents - beginning of year	0	0	0
Cash and cash equivalents - end of year	0	0	0
Combined Subsidiary Guarantors
Operating Activities
Net income (loss)	59,025	62,909	33,273
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	9,715	11,261	9,556
Deferred income taxes	17,765	21,036	10,000
Amortization of deferred financing costs	0	0	0
Stock-based compensation costs	0	0	0
Loss on extinguishment of debt	0	0	0
Premium payment on 2010 Senior Notes	0
Amortization of debt discount	0	0	0
Lease termination costs		0
Loss on disposal of equipment	(3)	21
Equity in income of subsidiaries	(4,052)	(1,482)	(1,313)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	12,460	(12,391)	(12,367)
Inventories	2,165	(6,360)	2,252
Prepaid expenses and other current assets	711	(135)	968
Accounts payable	(4,142)	20,687	4,139
Accrued liabilities	(2,664)	7,069	856
Net cash provided by operating activities	90,980	102,615	47,364
Investing Activities
Purchases of property and equipment	(108)	0	(239)
Proceeds from the sale of property and equipment	3	15
Proceeds from escrow of Blacksmith acquisition			1,200
Proceeds from the sale of Phazyme brand		21,700
Acquisition of brands	0		(662,800)
Acquisition of brands from GSK purchase price adjustments		(226)
Intercompany activity, net	0	226	661,600
Net cash (used in) provided by investing activities	(105)	21,715	(239)
Financing Activities
Repayments of long-term debt	0	0	0
Repayments under revolving credit agreement	0	0
Proceeds from issuance of Senior Notes	0		0
Repayment of 2010 Term Loan			0
Repayment of 2010 Senior Notes	0
Borrowings under revolving credit agreement	0	0
Proceeds from issuance of 2012 Term Loan			0
Payment of deferred financing costs	0	0	0
Proceeds from exercise of stock options	0	0	0
Excess tax benefits from share-based awards	0
Fair value of shares surrendered as payment of tax withholding	0		0
Intercompany activity, net	(90,875)	(124,330)	(47,125)
Net cash (used in) provided by financing activities	(90,875)	(124,330)	(47,125)
Effects of exchange rate changes on cash and cash equivalents	0	0	0
Increase (decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents - beginning of year	0	0	0
Cash and cash equivalents - end of year	0	0	0
Combined Non-guarantor Subsidiaries
Operating Activities
Net income (loss)	4,052	1,482	1,125
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	200	59	70
Deferred income taxes	(177)	(10)	(11)
Amortization of deferred financing costs	0	0	0
Stock-based compensation costs	0	0	0
Loss on extinguishment of debt	0	0	0
Premium payment on 2010 Senior Notes	0
Amortization of debt discount	0	0	0
Lease termination costs		0
Loss on disposal of equipment	0	0
Equity in income of subsidiaries	0	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(1,903)	(122)	(63)
Inventories	(2,832)	84	(1)
Prepaid expenses and other current assets	241	108	(359)
Accounts payable	628	136	(25)
Accrued liabilities	(594)	22	335
Net cash provided by operating activities	(385)	1,759	1,071
Investing Activities
Purchases of property and equipment	(186)	0	0
Proceeds from the sale of property and equipment	0	0
Proceeds from escrow of Blacksmith acquisition			0
Proceeds from the sale of Phazyme brand		0
Acquisition of brands	(55,215)		0
Acquisition of brands from GSK purchase price adjustments		0
Intercompany activity, net	55,215	0	0
Net cash (used in) provided by investing activities	(186)	0	0
Financing Activities
Repayments of long-term debt	0	0	0
Repayments under revolving credit agreement	0	0
Proceeds from issuance of Senior Notes	0		0
Repayment of 2010 Term Loan			0
Repayment of 2010 Senior Notes	0
Borrowings under revolving credit agreement	0	0
Proceeds from issuance of 2012 Term Loan			0
Payment of deferred financing costs	0	0	0
Proceeds from exercise of stock options	0	0	0
Excess tax benefits from share-based awards	0
Fair value of shares surrendered as payment of tax withholding	0		0
Intercompany activity, net	3,100	(1,549)	(914)
Net cash (used in) provided by financing activities	3,100	(1,549)	(914)
Effects of exchange rate changes on cash and cash equivalents	208	(54)	1
Increase (decrease) in cash and cash equivalents	2,737	156	158
Cash and cash equivalents - beginning of year	950	794	636
Cash and cash equivalents - end of year	3,687	950	794
Eliminations
Operating Activities
Net income (loss)	(125,637)	(139,561)	(74,076)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	0	0	0
Deferred income taxes	0	0	0
Amortization of deferred financing costs	0	0	0
Stock-based compensation costs	0	0	0
Loss on extinguishment of debt	0	0	0
Amortization of debt discount	0	0	0
Lease termination costs		0
Loss on disposal of equipment	0	0
Equity in income of subsidiaries	124,627	139,561	74,076
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	0	0	0
Inventories	1,010	0	0
Prepaid expenses and other current assets	0	0	0
Accounts payable	0	0	0
Accrued liabilities	0	0	0
Net cash provided by operating activities	0	0	0
Investing Activities
Purchases of property and equipment	0	0	0
Proceeds from the sale of property and equipment	0	0
Proceeds from escrow of Blacksmith acquisition			0
Proceeds from the sale of Phazyme brand		0
Acquisition of brands	0		0
Acquisition of brands from GSK purchase price adjustments		0
Intercompany activity, net	0	0	0
Net cash (used in) provided by investing activities	0	0	0
Financing Activities
Repayments of long-term debt	0	0	0
Repayments under revolving credit agreement	0	0
Proceeds from issuance of Senior Notes	0		0
Repayment of 2010 Term Loan			0
Repayment of 2010 Senior Notes	0
Borrowings under revolving credit agreement	0	0
Proceeds from issuance of 2012 Term Loan			0
Payment of deferred financing costs	0	0	0
Proceeds from exercise of stock options	0	0	0
Excess tax benefits from share-based awards	0
Fair value of shares surrendered as payment of tax withholding	0		0
Intercompany activity, net	0	0	0
Net cash (used in) provided by financing activities	0	0	0
Effects of exchange rate changes on cash and cash equivalents	0	0	0
Increase (decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents - beginning of year	0	0	0
Cash and cash equivalents - end of year	$ 0	$ 0	$ 0

Subsequent Events Subsequent Events (Details) (USD $) In Millions, except Share data, unless otherwise specified	0 Months Ended	12 Months Ended			0 Months Ended					12 Months Ended	0 Months Ended
	Aug. 06, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Apr. 25, 2014 Insight Pharmaceuticals Subsequent Event	Aug. 06, 2012 Stock Options	Nov. 05, 2013 Employee Restricted Stock Units (RSUs)	May 14, 2013 Employee Restricted Stock Units (RSUs)	May 09, 2012 Employee Restricted Stock Units (RSUs)	Mar. 31, 2014 Employee Restricted Stock Units (RSUs)	May 12, 2014 Employee Restricted Stock Units (RSUs) Subsequent Event	May 14, 2013 Employee Stock Options	May 12, 2014 Employee Stock Options Subsequent Event	May 14, 2013 Group One Employee Restricted Stock Units (RSUs)	May 12, 2014 Group One Employee Restricted Stock Units (RSUs) Subsequent Event	May 14, 2013 Group Two Employee Restricted Stock Units (RSUs)	May 12, 2014 Group Two Employee Restricted Stock Units (RSUs) Subsequent Event
Subsequent Event [Line Items]
Restricted common stock units granted in period, shares							6,000	113,637	111,152		96,638			55,637	75,638	58,000	21,000
Options granted in period												227,672	307,490
Award vesting period		10 months 13 days				3 years			3 years	3 years		3 years	3 years	3 years	3 years	3 years	3 years
Percentage of options vesting annually	33.30%								33.30%			33.30%	33.30%			33.30%	33.30%
Award exercisability period, from date of grant												10 years	10 years
Options granted, weighted-average grant-date fair value (in USD per share)	$ 15.66	$ 13.94	$ 6.03	$ 5.83								$ 29.94	$ 33.50
Purchase price, gross					$ 750.0

Schedule II Valuation and Qualifying Accounts (Details) (USD $)
In Thousands, unless otherwise specified

12 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Reserves for Sales Returns and Allowances

Movement in Valuation Allowances and Reserves [Roll Forward]

Valuation allowances and reserves, balance at beginning of year

$ 6,446

$ 4,257

$ 6,208

Amounts charged to expense

38,314

33,165

23,457

Deductions

(37,365)

(30,976)

(25,408)

Other

Valuation allowances and reserves, balance at end of year

7,395

6,446

4,257

Reserves for Trade Promotions

Movement in Valuation Allowances and Reserves [Roll Forward]

Valuation allowances and reserves, balance at beginning of year

8,523

5,506

4,853

Amounts charged to expense

39,967

41,041

32,185

^[1]

Deductions

(42,389)

(38,024)

(31,532)

Other

Valuation allowances and reserves, balance at end of year

6,101

8,523

5,506

Reserves for Consumer Coupon Redemptions

Movement in Valuation Allowances and Reserves [Roll Forward]

Valuation allowances and reserves, balance at beginning of year

4,249

3,509

2,723

Amounts charged to expense

2,755

8,282

7,180

^[1]

Deductions

(5,262)

(7,542)

(6,394)

Other

Valuation allowances and reserves, balance at end of year

1,742

4,249

3,509

Allowance for Doubtful Accounts

Movement in Valuation Allowances and Reserves [Roll Forward]

Valuation allowances and reserves, balance at beginning of year

863

604

444

Amounts charged to expense

134

265

200

Deductions

(6)

(40)

Other

^[2]

Valuation allowances and reserves, balance at end of year

1,035

863

604

PediaCare | Reserves for Trade Promotions

Movement in Valuation Allowances and Reserves [Roll Forward]

Amounts charged to expense

3,000

^[1]

PediaCare | Reserves for Consumer Coupon Redemptions

Movement in Valuation Allowances and Reserves [Roll Forward]

Amounts charged to expense

$ 2,000

[1]	We increased our reserves for Trade Promotion and Consumer Coupon Redemption by $3.0 million and $2.0 million, respectively, in an effort to gain market share for the PediaCare brand.
[2]	{F\|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOmQ5YjYyNDIxNmRkYTQ3NzNiNzRhNGFjNWViYmRkNjhifFRleHRTZWxlY3Rpb246NjYyMzJEN0VFNTYzMjkxQkVDQTg0QzE4QzAxNjg0QTgM}

Business and Basis of Presentation (Property and Equipment) (Details)	12 Months Ended
	Mar. 31, 2014
Machinery
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	5 years
Computer Equipment and Software
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives